Statera Biopharma (STAB) 10-K27 Feb 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Jun. 30, 2014	Feb. 12, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	CBLI
Entity Registrant Name	CLEVELAND BIOLABS INC
Entity Central Index Key	1318641
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding			3,435,534
Entity Public Float		$27,412,895

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$3,103,969	$10,048,466
Short-term investments		305,538
Accounts receivable	267,199	458,391
Other current assets	174,179	344,386
Total current assets	3,545,347	11,156,781
Equipment, net	244,537	457,912
Restricted cash	1,699,759	2,921,724
Other long-term assets	56,131	159,224
Investment in Incuron, LLC	4,268,458
Total assets	9,814,232	14,695,641
Current liabilities:
Accounts payable	1,057,743	794,397
Accrued expenses	1,804,456	2,445,446
Deferred revenue	156,317	1,069,438
Accrued warrant liability	862,074	1,241,311
Current portion of notes payable	2,640,968	351,527
Current portion of capital lease obligation	7,522	83,634
Total current liabilities	6,529,080	5,985,753
Noncurrent portion of capital lease obligation		7,522
Long-term debt	1,499,050	7,121,388
Commitments and contingencies
Total liabilities	8,028,130	13,114,663
Stockholders' equity:
Additional paid-in capital	132,693,988	125,723,083
Other comprehensive income/(loss)	-380,110	307,339
Accumulated deficit	-133,935,562	-135,564,666
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2014 and 2013, respectively
Common stock, $.005 par value; 160,000,000 shares authorized, 2,858,126 and 2,259,818 shares issued and outstanding as of December 31, 2014 and 2013, respectively	14,287	11,299
Total Cleveland BioLabs, Inc. stockholders' equity (deficit)	-1,607,397	-9,522,945
Noncontrolling interest in stockholders' equity	3,393,499	11,103,923
Total stockholders' equity	1,786,102	1,580,978
Total liabilities and stockholders' equity	$9,814,232	$14,695,641

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	2,858,126	2,259,818
Common stock, shares outstanding	2,858,126	2,259,818

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Grants and contracts	$3,701,899	$8,487,966	$3,570,710
Operating expenses:
Research and development	9,654,144	19,525,950	22,501,805
General and administrative	8,469,690	12,038,775	11,115,511
Total operating expenses	18,123,834	31,564,725	33,617,316
Loss from operations	-14,421,935	-23,076,759	-30,046,606
Other income (expense):
Interest and other income (expense)	-1,089,582	44,925	295,123
Foreign exchange gain (loss)	-1,036,459	38,202	-365,138
Gain on deconsolidation of Incuron, LLC	14,206,555
Change in value of warrant liability	2,662,329	2,864,348	7,701,981
Equity in loss of Incuron, LLC	-285,542
Total other income	14,457,301	2,947,475	7,631,966
Net income (loss)	35,366	-20,129,284	-22,414,640
Net loss attributable to noncontrolling interests	1,593,738	2,866,407	4,180,498
Net income (loss) attributable to Cleveland BioLabs, Inc.	$1,629,104	($17,262,877)	($18,234,142)
Net income (loss) available to common stockholders per share of common stock, basic and diluted	$0.60	($7.67)	($9.75)
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted	2,702,884	2,250,142	1,869,443

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income (loss) including noncontrolling interests	$35,366	($20,129,284)	($22,414,640)
Other comprehensive loss
Foreign currency translation adjustment	-1,816,840	-421,345	797,558
Comprehensive income (loss) including noncontrolling interests	1,781,474	-20,550,629	-21,617,082
Comprehensive loss attributable to noncontrolling interests	2,477,469	3,048,618	3,844,800
Comprehensive income (loss) attributable to Cleveland BioLabs, Inc.	$695,995	($17,502,011)	($17,772,282)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income (loss)	$35,366	($20,129,284)	($22,414,640)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	200,792	376,213	479,595
Amortization of loan costs	640,248	94,995
Unrealized currency loss on short-term investments			52,726
(Gain) loss on equipment disposal	24,685	-3,222	18,997
Impairment loss on property and equipment		293,162
Noncash compensation	496,470	1,473,449	2,535,217
Warrant issuance costs	171,116		244,857
Equity in loss of Incuron, LLC	285,542
Change in value of warrant liability	-2,662,329	-2,864,348	-7,701,981
Gain on deconsolidation of Incuron, LLC	-14,206,555
Changes in operating assets and liabilities:
Accounts receivable	629,397	-416,495	1,736,199
Other current assets	-1,242	697,966	-182,428
Other long-term assets	15,690	-29,732	-6,414
Accounts payable	459,337	-713,502	609,522
Deferred revenue	-756,808	-2,062,332	3,238,124
Accrued expenses	213,104	180,483	740,723
Net cash used in operating activities	-14,455,187	-23,102,647	-20,649,503
Cash flows from investing activities:
Purchase of short-term investments	-1,408,169		-5,220,781
Sale of short-term investments	1,689,670	2,197,940	8,312,120
Purchase of equipment	-20,222	-139,491	-178,271
Cash divested upon deconsolidation of Incuron, LLC	-2,048,023
Increase in restricted cash		-1,497,740	-1,541,366
Net cash provided by (used in)investing activities	-1,786,744	560,709	1,371,702
Cash flows from financing activities:
Issuance of common stock, net of offering costs	9,697,501		15,675,727
Net proceeds/(repayment) of long-term debt	-4,176,275	7,327,675
Noncontrolling interest capital contribution to Incuron, LLC	5,152,438		5,893,557
Exercise of options		12,392	2,375
Repayment of capital lease obligation	-83,634	-78,125	-52,410
Net cash provided by financing activities	10,590,030	7,261,942	21,519,249
Effect of exchange rate change on cash and equivalents	-1,292,595	-323,621	538,046
Decrease in cash and cash equivalents	-6,944,497	-15,603,617	2,779,494
Cash and cash equivalents at beginning of period	10,048,466	25,652,083	22,872,589
Cash and cash equivalents at end of period	3,103,969	10,048,466	25,652,083
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	451,327	17,105	23,708
Supplemental schedule of noncash financing activities:
Noncash warrant issuance costs	15,993	117,999
Equipment acquired through lease financing			221,690
Warrants [Member]
Supplemental schedule of noncash financing activities:
Allocation of equity proceeds to fair value of warrants	$2,216,593

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interests [Member]
Beginning balance at Dec. 31, 2011	$22,245,496	$8,907	$109,034,800	$84,613	($100,067,647)	$13,184,824
Beginning balance, Shares at Dec. 31, 2011		1,781,319
Issuance of common stock net of offering costs	15,920,584	2,131	15,918,453
Issuance of common stock, net of offering costs, shares		426,250
Allocation of debt proceeds to fair value of warrants	-4,521,681		-4,521,681
Noncontrolling interest capital contribution	5,893,557		1,081,040			4,812,517
Stock based compensation	2,562,459	148	2,562,311
Stock based compensation, Shares		29,601
Exercise of options	2,375	0	2,375
Exercise of options, shares		63
Net income (loss)	-22,414,640				-18,234,142	-4,180,498
Foreign currency translation	797,558			461,860		335,698
Ending balance at Dec. 31, 2012	20,485,708	11,186	124,077,297	546,473	-118,301,789	14,152,541
Ending balance, Shares at Dec. 31, 2012		2,237,233
Allocation of debt proceeds to fair value of warrants	117,999		117,999
Stock based compensation	1,515,509	111	1,515,399
Stock based compensation, Shares		22,100
Exercise of options	12,391	2	12,389
Exercise of options, shares		485
Net income (loss)	-20,129,284				-17,262,877	-2,866,407
Foreign currency translation	-421,345			-239,134		-182,211
Ending balance at Dec. 31, 2013	1,580,978	11,299	125,723,083	307,339	-135,564,666	11,103,923
Ending balance, Shares at Dec. 31, 2013		2,259,818
Issuance of common stock net of offering costs	9,802,118	2,976	9,799,142
Issuance of common stock, net of offering costs, shares		595,256
Allocation of debt proceeds to fair value of warrants	-2,216,593		-2,216,593
Noncontrolling interest capital contribution	5,152,283		1,176,982			3,975,301
Stock based compensation	645,500	12	645,488
Stock based compensation, Shares		3,052
Deconsolidation of Incuron, LLC	-11,396,710		-2,434,114	245,660		-9,208,256
Exercise of options, shares
Net income (loss)	35,366				1,629,104	-1,593,738
Foreign currency translation	-1,816,840			-933,109		-883,731
Ending balance at Dec. 31, 2014	$1,786,102	$14,287	$132,693,988	($380,110)	($133,935,562)	$3,393,499
Ending balance, Shares at Dec. 31, 2014		2,858,126

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parenthetical) (Common Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012
Common Stock [Member]
Offering costs	$697,882	$1,129,916

Description_of_Business

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2014
Accounting Policies [Abstract]
Description of Business	1. Description of Business

	Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We conduct business in the United States and in the Russian Federation, or Russia, through several legal entities, one of which is wholly-owned and two of which are owned in collaboration with financial partners. As used throughout these consolidated financial statements, the terms “Cleveland BioLabs” and “CBLI” refer to Cleveland BioLabs, Inc. and its wholly-owned subsidiary BioLab 612, LLC, but not its consolidated joint venture, Panacela Labs, Inc. or its unconsolidated joint venture, Incuron, LLC. The “Company,” “we,” “us” and “our” refer to Cleveland BioLabs, Inc. together with its wholly-owned subsidiary BioLab 612, LLC, its consolidated joint venture, Panacela Labs, Inc., and its unconsolidated joint venture, Incuron, LLC.

	CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. As of December 31, 2014, CBLI had one wholly-owned subsidiary, Biolab 612, LLC, or Biolab 612, which began operations in 2012, one consolidated joint venture, Panacela Labs, Inc., or Panacela, which was formed by us and a financial partner in 2011, and one unconsolidated joint venture, Incuron, LLC, or Incuron, which was formed by us and a financial partner in 2010. Additionally, Panacela had a wholly-owned subsidiary, Panacela Labs, LLC, which was formed in 2011.

Summary_of_Significant_Account

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The accompanying consolidated financial statements include the accounts of CBLI and the subsidiary and joint venture in which CBLI held a controlling interest in as of December 31, 2014, BioLab 612 and Panacela. The accounts of Incuron are also included through November 25, 2014, the date at which CBLI no longer maintained a controlling interest in Incuron. For the period from November 25, 2014 through December 31, 2014, the Company’s interest in Incuron has been presented under the equity method of accounting. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States, or GAAP.

On January 28, 2015, the Company, after receiving authorization from the Company’s shareholders and board of directors, executed a reverse stock split, or Reverse Split, of the Company’s common stock at the ratio of 1:20. All historical share balances and share price-related data have been adjusted based on this ratio.

At December 31, 2014, we had cash, cash equivalents and short-term investments of $3.1 million, $6.8 million after giving effect to our equity raise on February 6, 2015 described in Note 14 to the Consolidated Financial Statements. Of that total, $0.5 million was restricted for the use of our consolidated joint venture, Panacela, leaving $2.6 million available for general use, or $6.3 million giving effect to the February 2015 raise, which management believes will be sufficient to support operations into June 2015. To ensure continuing operations beyond that point, management is evaluating all opportunities to secure additional financing, including investments from non-controlling interests, the sale or license of our drug candidates, the issuance of equity and additional revenues from the U.S. or Russian governments. Management believes that sufficient sources of financing will be available to support operations into the future, however there can be no assurances at this time. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Of the $3.1 million and $10.0 million of cash and cash equivalents at December 31, 2014 and December 31, 2013, respectively, $0 million and $3.5 million, respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of commercial paper, short-term debt securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of December 31, 2014, $0.5 million of the Company’s cash and cash equivalents were restricted to the use of our consolidated joint venture, Panacela, leaving $2.6 million available for general use.

Short-Term Investments

The Company’s short-term investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Accordingly, these investments are carried at amortized cost. Short-term investments classified as held-to-maturity consisted of certificates of deposit with maturity dates beyond three months and less than one year. The Company’s short-term investments were $0.0 million and $0.3 million as of December 31, 2014 and 2013, respectively and were restricted for use by its consolidated joint ventures.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

As of December 31, 2014, the Company held 43% of its cash and cash equivalents in accounts located outside of the United States.

As of February 12, 2015, the Russian Ruble: Dollar exchange rate increased from 56.2584 to 66.0585, resulting in a decrease of $0.2 million to the Company’s cash and cash equivalents as compared to December 31, 2014.

Significant Customers and Accounts Receivable

Grant and contract revenue from the United States government accounted for 0.6%, 26.8% and 34.8% of total revenue for the years ended December 31, 2014, 2013 and 2012, respectively. Although the Company anticipates ongoing U.S. and Russian government contract and grant revenue, there is no guarantee that these revenue streams will continue in the future.

Grant and contract revenue received by our subsidiary/joint ventures from Russian government agencies accounted for 95.2%, 73.2% and 65.2% of total revenues for the years ended December 31, 2014, 2013 and 2012, respectively.

Service contract revenue received by us from Incuron accounted for 4.2%, 0.0% and 0.0% of total revenues for the years ended December 31, 2014, 2013 and 2012, respectively.

Accounts receivable consist of amounts due under contracts with certain government and foreign entities. The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days.

Management estimates an allowance for doubtful accounts that is based upon management’s review of delinquent accounts and an assessment of the Company’s historical evidence of collections. There were allowances for doubtful accounts of $0.1 and $0.0 million at December 31, 2014 and December 31, 2013, respectively, pertaining to accounts receivable from our subleases.

Equipment

Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred.

Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:

Asset Category

Estimated Useful Life

(in Years)

Laboratory equipment

Furniture and fixtures

Computer equipment

Impairment of Long-Lived Assets

Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value.

In connection with the restructuring discussed in Note 8, “Restructuring,” the Company entered into an equipment lease agreement with Buffalo BioLabs, LLC, or BBL, effective January 1, 2014 for the equipment used by the employees transitioned to BBL. The estimated fair value of those assets using a discounted cash flow approach was $243,000. Comparing this fair value to the carrying amount of the equipment as of December 31, 2013 of $536,000 resulted in a $293,000 write-down of the assets, which was included in research and development expenses for the year ended December 31, 2013.

Restricted Cash

Restricted cash at December 31, 2014 includes certificates of deposit denominated in Russian Rubles and posted by Panacela and BioLab 612 as collateral for performance guarantees for their contracts with the Ministry of Industry and Trade of the Russian Federation. The guarantees require Panacela and BioLab 612 to satisfactorily perform their statements of work under the contracts. Both Panacela and BioLab 612 anticipate receiving the full proceeds of their deposits at the completion of the contracts, which for each contract is more than a year away. As a consequence, all of the Company’s restricted cash is classified as a noncurrent asset.

Equity Method Investment

The Company’s equity method investment includes its minority holdings in Incuron. The opening equity investment amount as of November 25, 2014, the date at which we no longer maintained a controlling interest, was determined to be $4,554,000. This determination was made by an independent valuation expert based on the commercial potential of Incuron’s drug candidates and market values assigned to other early-stage oncology drug candidates.

Under the equity method, the carrying amount of the investment is adjusted for the Company’s share of earnings and losses, as well as any capital contributions to and distributions from Incuron. The Company classifies income and losses related to its equity method investments as a component of operating income or loss as Incuron is an extension of the Company’s core business. The Company evaluates equity investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may have experienced an “other-than-temporary” decline in value. If such conditions exist, the Company compares the estimated fair value of the investment to its carrying value to determine if an impairment is indicated and whether the impairment is “other-than-temporary” based on an assessment of all relevant factors, including consideration of the intent and ability to retain the investment.

Intellectual Property

Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.

Deferred Revenue

Deferred revenue represents cash received under grants and contracts in excess of the revenue recognizable through the end of the respective financial reporting period. The revenue associated with these advances will be recognized in future periods as the applicable costs are incurred.

Accrued Warrant Liability

Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification, or the Codification, on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the statements of operations as “Change in value of warrant liability.”

The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity.

Foreign Currency Translation

The Russian ruble is the functional currency of our foreign subsidiary and joint ventures, which are all located in the Russian Federation. Assets and liabilities of these companies are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss).

Revenue Recognition

The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work.

Research and Development

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries, fringe benefits, materials and related expenses for personnel and facility expenses. Other research and development expenses include fees paid to consultants and outside service providers, the costs of materials used in clinical trials and research and development and stock-based compensation.

Accounting for Stock-Based Compensation

The 2006 Equity Incentive Plan, as amended, or the “Plan”, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. At the 2012 annual meeting of stockholders, an amendment to increase the maximum number of shares of common stock reserved for issuance under the Plan was approved, and as of December 31, 2014, an aggregate of 500,000 shares of common stock were authorized for issuance under the Plan, of which a total of approximately 100,000 shares of common stock remained available for future awards. A single participant cannot be awarded more than 20,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by compensation committee of the CBLI board of directors.

The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:

For the year ended December 31,

2014

2013

2012

Risk-free interest rate

1.59 - 1.98

.02 - 1.92

.65 - 1.49

Expected dividend yield

Expected life

5 - 6 Years

5 - 7.3 Years

5 - 6 Years

Expected volatility

71.24 - 78.02

78.62 - 89.66

86.58 - 92.60

“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.

“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.

“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.

In June 2013, CBLI’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of CBLI, and certain designated related corporations may be given an opportunity to purchase shares of CBLI common stock. As of December 31, 2014, there were 115,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) 10,000 shares of common stock. The ESPP, when implemented, will allow employees to use up to 15% of their compensation, up to $25,000 per year, to purchase shares of common stock at an amount equal to 85% of the fair market value of the our common stock on the offering date or the purchase date, whichever is less.

Income taxes

No income tax expense was recorded for the years ended December 31, 2014, 2013 and 2012, as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset.

Earnings/(loss) per share

Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.

The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:

As of December 31,

Common Equivalent Securities

2014

2013

2012

Warrants

875,304

526,752

518,939

Options

261,389

278,242

250,849

Total

1,136,693

804,994

769,788

Comprehensive Income (Loss)

The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers, which updates the principles for recognizing revenue. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition, and as such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company is evaluating the potential impacts of the new standard on its existing stock-based compensation plans.

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, ASU 2014-15 requires that an entity’s management evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. ASU 2014-15 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company is evaluating the potential impacts of this new standard on its quarterly reporting process.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements

	The Company measures and records cash equivalents and warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:


		•		Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets;


		•		Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and


		•		Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.

	The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 and December 31, 2013:



			As of December 31, 2014
			Level 1				Level 2				Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—			$	—			$	862,074		$	862,074
	Compensatory stock options not yet issued (1)			—				—				132,295			132,295

	Total liabilities		$	—			$	—			$	994,369		$	994,369


			As of December 31, 2013
			Level 1				Level 2				Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—			$	—			$	1,241,311		$	1,241,311
	Compensatory stock options not yet issued (1)			—				—				309,450			309,450

	Total liabilities		$	—			$	—			$	1,550,761		$	1,550,761



	-1	Included in accrued expenses in the accompanying consolidated balance sheets.

	The Company has certain warrants that could require settlement in cash if a fundamental transaction occurs, as defined in the respective agreements. These agreements specify the amount due to warrant holders is based on the Black-Scholes pricing model. The following are the assumptions used to measure the accrued warrant liability at December 31, 2014 and 2013, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2, “Summary of Significant Accounting Policies”:



			December 31, 2014				December 31, 2013
	Stock Price		$	5.6			$	23.4
	Exercise Price		$	10.10 - 100.00			$	32.00 - 100.00
	Term in years			0.46 - 6.04				0.59 - 1.91
	Volatility			70.69 - 100.08	%			42.52 - 76.03	%
	Annual rate of quarterly dividends			0	%			0	%
	Discount rate- bond equivalent yield			.12 - 1.65	%			.08 - .36	%



	The following are the assumptions used to measure the compensatory stock options not yet issued at December 31, 2014:



			December 31, 2014
	Stock price		$	5.6
	Term in years			5
	Volatility			73.99	%
	Annual rate of quarterly dividends			0	%
	Discount rate – bond equivalent yield			1.45	%

	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the year ended December 31, 2014 and 2013:



		Year Ended December 31, 2014
		Accrued Warrant				Compensatory
		Liability				Stock Options
						Issued After
						Year End
Beginning Balance		$	1,241,311			$	309,450
Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(2,572,035	)			(21,055	)
Issuances			2,283,092				132,295
Settlements			(90,294	)			(288,395	)

Balance, December 31, 2014		$	862,074			$	132,295


		Year Ended December 31, 2013
		Accrued Warrant				Compensatory
		Liability				Stock Options
						Issued After
						Year End
Beginning Balance		$	4,105,659			$	—
Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(2,864,348	)			—
Estimates and other changes in fair value			—				309,450

Balance, December 31, 2013		$	1,241,311			$	309,450



-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. For the year ended December 31, 2014 we realized a gain of $90,294 in connection with the elimination of the Series B warrants issued to an investor in the January 2014 equity investment transaction. For the year ended December 31, 2013 there were no realized gains or losses.
-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. As of December 31, 2014 and 2013, the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis.



The Company considers the accrued warrant liability and compensatory stock options not yet issued to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. The compensatory stock options not yet issued use management’s estimate for the expected term, which is based on the safe harbor method as historical exercise information over the term of each security is not readily available. The following table summarizes the unobservable inputs into the fair value measurements:



		December 31, 2014
Description		Fair Value				Valuation Technique				Unobservable Input			Range in years
Compensatory stock options not yet issued		$	132,295				Black-scholes pricing model				Expected term			5
Accrued warrant liability			862,074				Black-scholes pricing model				Expected term			0.46 - 6.04

		$	994,369


Management believes the value of the accrued warrant liability and compensatory stock options are more sensitive to changes in the Company’s stock price at the end of the respective reporting period as opposed to changes in the expected term. At December 31, 2014, a 10% increase in the expected term of the Company’s warrants measured using the Black-Scholes pricing model would increase the warrant liability by approximately 13%, while a 10% decrease in the expected term would decrease the warrant liability by approximately 14%. A 10% increase in the Company’s stock price would result in an increase in the accrued warrant liability of approximately 17%, while a 10% decrease in the stock price would decrease the warrant liability by approximately 16%. At December 31, 2014, a 10% increase or decrease in the expected term of the Company’s compensatory stock options not yet issued would increase or decrease the amount accrued by approximately 4%, while a 10% increase or decrease in the stock price would increase or decrease the amount accrued by approximately 10%.

The carrying amounts of the Company’s remaining financial instruments, which include cash, short-term investments, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Equipment

Equipment	12 Months Ended
Equipment	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Equipment	4. Equipment
	The following table summarizes the Company’s gross equipment costs for the years ended December 31, 2014 and 2013:


		As of December 31,
		2014			2013

	Lab equipment	$	1,062,679		$	1,083,463
	Computer equipment		293,663			332,386
	Furniture		528,807			528,807

			1,885,149			1,944,656
	Less accumulated depreciation		(1,640,612	)		(1,486,744	)


	Equipment, net	$	244,537		$	457,912

	As part of the sublease income received from Buffalo BioLabs, Inc. mentioned in Note 9, Significant Alliances and Related Parties, the Company leases lab equipment to Buffalo BioLabs, Inc. The original cost and net book value of that equipment as of December 31, 2014 was $1,054,166 and $137,553, respectively. The monthly income we receive from Buffalo BioLabs, Inc. for this equipment is $4,500 and is cancellable upon 90 days notice.

Noncontrolling_Interests

Noncontrolling Interests	12 Months Ended
Noncontrolling Interests	Dec. 31, 2014
Noncontrolling Interest [Abstract]
Noncontrolling Interests	5. Noncontrolling Interests
	On May 31, 2012, Bioprocess Capital Ventures, or BCV, our financial partner in Incuron, contributed approximately 194.0 million Russian rubles (approximately $5.9 million) to Incuron, which increased its ownership percentage to 40.78% and decreased CBLI’s ownership percentage to 59.22%, which is the ownership percentage at December 31, 2013. On June 20, 2014, BCV contributed 100.0 million Russian rubles (approximately $2.9 million) to Incuron, which increased its ownership interest from 40.78% to 46.06% and decreased CBLI’s ownership percentage from 59.22% to 53.94%. The effect of this change in CBLI’s ownership interest in Incuron on CBLI’s equity is shown on the consolidated statement of stockholders’ equity. On August 5, 2014, BCV contributed an additional 79.9 million Russian rubles (approximately $2.3 million) to Incuron which increased its ownership interest from 46.06% to 49.98%. On November 25, 2014, BCV exercised their rights under Amendment 1 to the Participation Agreement and purchased 3.05% of Incuron from us for a nominal amount. As a result, effective November 25, 2014 CBLI no longer maintained control of Incuron, owning 46.96%, and deconsolidated Incuron. The Company’s consolidated income statement includes revenue, research and development, and general and administrative expenses recognized by Incuron through November 25, 2014 in the amounts of $1,000,770, $1,664,094 and $907,643, respectively.
	Beginning on November 25, 2014, CBLI accounted for its ownership interest in Incuron using the equity method of accounting, and recognized its share of equity method losses in the amount of $285,542. The gain on deconsolidation of Incuron amounted to $14,206,555, and was determined based on comparison of the fair value of CBLI’s retained investment in Incuron of $4,554,000 and the carrying amount of the non-controlling interest on the deconsolidation date of $9,797,083, less the carrying amount of the net assets of Incuron on the deconsolidation date of $144,528.
	The fair value of Incuron at the date of deconsolidation was determined by an independent valuation. This fair value is categorized within Level 3 of the fair value hierarchy. The value was determined by weighting a market approach and an income approach (Risk adjusted debt-free discounted cash flow) using equal weights of 50% and adjusted for uncertainties associated with the Russian capital markets. The unobservable input of the market approach was a 0.5 multiple of market value to invested capital. The unobservable input to the income approach was a discount rate based upon a weighted average cost of capital of 22%.
	We anticipate that CBLI will continue to provide services to Incuron in a related party capacity following the date of deconsolidation to assist in furthering the development of CBL0137. Since the date of the deconsolidation, the Company recognized $154,687 of revenues associated with executed services contracts. As of the year ended December 31, 2014, the Company has $156,464 in accounts receivable with Incuron. A summary of Incuron’s financial position and results of operations follows:


	December 31, 2014
	ASSETS				LIABILITIES AND EQUITY
	Cash and cash equivalents	$	1,103,384		Accounts payable	$	33,303
	Short-term investments		248,852		Accounts payable to CBLI		156,464
	Other current assets		47,846		Accrued expenses		253,915

	Total current assets		1,400,082		Total current liabilities		443,681
	Long-term assets		6,900		Net equity		963,300

	Total assets	$	1,406,982		Total liabilities and equity	$	1,406,982

	STATEMENT OF OPERATIONS
	For the period from
	November 26, 2014 to December 31, 2014

	REVENUES
	Grant and contract revenue	$	—
	OPERATING EXPENSES
	Research and development		215,392
	CBLI development costs		169,511
	General and administrative		106,277

	Total operating expenses		491,180

	LOSS FROM OPERATIONS		(491,180	)
	OTHER EXPENSES
	Foreign exchange gain (loss)		(116,874	)

	NET INCOME/(LOSS)	$	(608,054	)


	In 2011, CBLI and Open Joint Stock Company “Rusnano”, or Rusnano, and certain other third-party technology providers formed Panacela to develop and commercialize a early-stage drug candidates for the treatment of oncological, infectious or other diseases. CBLI invested $3.0 million, certain third-party owners, assigned and/or provided exclusive licenses, and Rusnano invested $9.0 million, with an additional $17.0 million available for investment. $1.5 million of the $17.0 million was invested in the form of a convertible loan, discussed in Note 6, “Debt,” leaving $15.5 million currently available to be invested at Rusnano’s option. At December 31, 2014, CBLI had an ownership stake of 57.78% in Panacela.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	6. Debt
	On September 30, 2013, CBLI and BioLab 612 entered into a Loan and Security Agreement, or the Loan Agreement, with Hercules Technology II, L.P., or Hercules, pursuant to which we issued a $6.0 million note and received net proceeds of $5.9 million. The loan bears interest at the greater of (i) 10.45% per annum or (ii) 10.45% plus the prevailing prime rate minus 4.25%. The loan matures on January 1, 2017, and requires interest-only payments for the initial 12 months and principal and interest payments in 27 monthly installments thereafter. In June 2014, CBLI repaid $4.0 million of the Hercules Loan using net proceeds from a sale of equity and cash.
	In connection with the Loan Agreement, CBLI granted a first priority lien in substantially all of CBLI’s assets (exclusive of intellectual property). The Loan Agreement also contains representations and warranties by CBLI and Hercules, indemnification provisions in favor of Hercules, customary covenants (including limitations on other indebtedness, liens, acquisitions, investments and dividends, but excluding any financial covenants), and events of default (including payment defaults, breaches of covenants, material adverse events and events leading to bankruptcy or insolvency). Prepayment of the loan is subject to a penalty rate applied to the balance of the secured obligation and ranges from 1% to 3% based on the date the loan is prepaid. The prepayment penalty was waived on connection with the above referenced June 2014 prepayment.
	Additional loan features, all of which are recorded debt issuance costs and loan discounts in non-current assets, include: $102,000 related to legal fees and a $100,000 facility fee both of which were paid in cash. A $550,000 “end-of-term charge” which is due upon full repayment of the loan or on the maturity date, whichever occurs sooner and is included in long-term liabilities. And a five-year warrant to purchase 7,813 shares of CBLI common stock. The warrant had an initial exercise price of $32.00 per share, which was subsequently lowered to $10.10 per share in accordance with its terms. The Black-Scholes pricing model yielded $117,999 as the fair value of the warrant upon issuance which was recorded as equity.
	CBLI will amortize the loan discounts and debt issuance costs to interest expense over the term of the loan using the effective interest rate method, which approximates 16.6%.
	The following schedule shows the payments for principal and the end of term charge on the Hercules loan by calendar year:


	2015	$	748,738
	2016		831,721
	2017		852,365

	Total	$	2,432,824

	On September 3, 2013, Panacela entered into a Master Agreement, or the Panacela Loan, with Rusnano and CBLI pursuant to which Panacela issued a $1,530,000 note to Rusnano. The Panacela Loan bears interest at a rate of 16.3% per annum and matures on September 10, 2015, at which time Panacela must repay all unpaid principal and accrued interest. As of the year ended December 31, 2014, Panacela had $355,493 of interest accrued associated with the Panacela Loan. Prior to March 10, 2015, the loan is mandatorily convertible into shares of Panacela preferred stock at a conversion price of $1,057 per share if Panacela completes a qualified financing in accordance with the terms of the Panacela Loan. Subsequent to March 10, 2015, Rusnano has the option to convert the unpaid principal plus interest into shares of Panacela preferred stock at a conversion price of $1,057 per share, or if Panacela has a qualified financing event, at a discounted price of 0.75 times the purchase price per share.

	In connection with the Panacela Loan, CBLI issued Rusnano a warrant that has an exercise period that begins upon an event of default on the Panacela Loan and expires on December 31, 2016. Upon an event of default, Rusnano has the option to assign 69.2% of the unpaid principal and interest under the Panacela Loan to CBLI in exchange for shares of CBLI common stock at a price of $33.88 per share.
	For the years ended December 31, 2014 and 2013, we recognized interest expense of $1,340,639 and $338,112 for these loans, respectively. Included in the $1,340,639 of interest expense recognized for the year ended December 31, 2014 was a $401,803 non-cash write-off of debt issuance costs associated with the $4.0 million early loan repayment in June 2014.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity
	On January 27, 2015, the Company’s stockholders approved the Reverse Split of one share for each twenty shares outstanding (1:20). The Reverse Split became effective as of the open of trading on the NASDAQ Capital Market on January 28, 2015. All shares of Common Stock, warrants, options, per share data and exercise prices included in these financial statements and notes for all periods presented have been retroactively adjusted to reflect the Reverse Split with respect to the Company’s shares of Common Stock.
	On June 20, 2014, the Company completed a sale of units that were immediately separable into an aggregate of 308,370 shares of the Company’s common stock and warrants to purchase up to 154,186 additional shares of the Company’s common stock issuable upon the exercise of a warrant. Each unit was sold for $11.35, which qualified as an “at market” transaction as determined by NASDAQ, resulting in net proceeds of approximately $3.3 million after deducting for placement agent fees and offering expenses. In connection with the sale, the Company issued Series J warrants for 154,186 shares of common stock to the purchasers, and 1,324 Series J warrants to the placement agent. Each Series J warrant has an exercise price of $11.20 per share, and will expire five years from the date of issuance. The sale also triggered a reduction in the exercise price of 228,891 of the Company’s warrants to $10.10.
	On January 16, 2014, the Company completed a public offering of 286,886 shares of the Company’s common stock at a price of $24.40 per share, resulting in net proceeds of approximately $6.4 million after deducting for placement agent fees and offering expenses. In connection with the offering, the Company issued Series A warrants for 143,445 shares of common stock and Series B warrants for 143,445 shares of common stock to the purchasers. Each Series A warrant has an exercise price of $24.40 per share, and will become exercisable nine months following the date of issuance and expire five years from the date of issuance. Each Series B warrant has an exercise price of $24.40 per share, and became exercisable nine months following the date of issuance and will expire 18 months from the date of issuance. In addition to the warrants issued to the purchasers, the Company also issued Series A warrants for an aggregate of 4,306 shares of common stock and Series B warrants for an aggregate of 4,306 shares of common stock to the placement agent as compensation for completing the offering. The warrants to the placement agent have the same terms, including exercise price, as the warrants issued to investors. The offering also triggered a reduction in the exercise price of 221,078 of the Company’s warrants to $24.40.
	The January 2014 Series A and B warrants contain provisions that could require the Company to settle the warrants in cash, and accordingly, have been classified as a liability. The fair value of the January Series A and B warrants amounted to $2,283,092 and was determined based on the following assumptions using the Black-Scholes valuation model:


			January 16,
			2014
	Stock price		$	24.6
	Exercise price		$	24.4
	Term in years			.75 - 2.50
	Expected volatility			43.06 - 79.86	%
	Expected dividend yield			0	%
	Risk-free interest rate			.09 - .58	%

	On September 4, 2014, the Company and certain investors in the January 16, 2014 public offering discussed above amended the Securities Purchase Agreement to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In addition, the same investors returned January 2014 Series B warrants to purchase, in the aggregate, 102,460 shares of the Company’s common stock for cancellation. In exchange for these concessions, the Company agreed to extend the expiration dates from January 16, 2019 to January 16, 2021 for Series A warrants to purchase 102,460 shares of the Company’s common stock, and reduced the exercise price from $24.40 to $20.40.
	On September 29, 2014, the Company and certain investors amended a Securities Purchase Agreement, dated as of February 13, 2009, to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In exchange, the Company agreed to extend the expiration dates from February 13, 2016 to March 30, 2018 on Series D warrants to purchase 174,307 shares of the Company’s common stock, and revised the anti-dilution provision in the Series D warrants to include variable rate transactions.
	On January 9, 2015, the Company and certain investors amended a Securities Purchase Agreement, dated as of February 25, 2010, to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In exchange, the Company agreed to extend the expiration dates from March 2, 2015 to March 2, 2017 on warrants to purchase 46,771 shares of the Company’s common stock, and revised the anti-dilution provision to include variable rate transactions.
	In October 2012, CBLI completed a public offering of 187,500 units at a price of $40.00 per unit, with each unit consisting of one share of CBLI common stock, and one warrant to purchase 0.5 of a share of CBLI common stock at an exercise price of $60.00 per whole share, or the 2012 Offering. The shares of CBLI common stock and the warrants issued in the 2012 Offering were issued separately. Under the terms of the related underwriting agreement, CBLI granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 56,250 shares of CBLI common stock (with an over-allotment price of $39.90 per share) and/or additional warrants to purchase up to 28,125 shares of CBLI common stock (with an over-allotment price of $0.19 for each warrant to purchase a whole share) to cover over-allotments, if any. The underwriter exercised their option in part by purchasing 51,250 shares and 28,125 warrants of the over-allotment option within 30 days of the closing.
	Certain warrants issued during the 2012 offering contain provisions that could require the Company to settle the warrants in cash and, accordingly, were originally recorded as a liability in the amount of $4,521,681 determined by the Black-Scholes valuation model with the following assumptions:


	Stock price		$	49.6
	Exercise price		$	60
	Term in years			2.51
	Expected volatility			79.7	%
	Expected dividend yield			0	%
	Risk-free interest rate			0.35	%
	The 2012 Offering triggered a reduction in the exercise price of 46,771 of the Company’s warrants to $40.00.

	The following table sets forth the changes in the number of warrants outstanding for the periods presented, exclusive of the warrants issued to Rusnano in connection with their loan to Panacela as those warrants are not exercisable until the occurrence of an event of default, which has not occurred:


			Number of				Weighted Average
			Warrants				Exercise Price
	Outstanding at December 31, 2012			518,939			$	58.8
	Granted			7,813				32
	Forfeited, Canceled			—				—

	Outstanding at December 31, 2013			526,752				54
	Granted			451,012				19.85
	Forfeited, Canceled			(102,460	)			24.4

	Outstanding at December 31, 2014			875,304				33.72

	Equity Incentive Plan
	The following is a summary of option award activity under the Plan for the year ended December 31, 2014:


			Year Ended December 31, 2014
			Total Stock Options				Weighted Average		Nonvested Stock			Weighted Average
			Outstanding				Exercise Price per		Options			Grant Date Fair
							Share					Value per Share
	December 31, 2013			278,390			$	82.9		29,724		$	29.97
	Granted			49,550				12.48		2,405			6.73
	Vested			—				—		(5,155	)		51.85
	Exercised			—				—		—			—
	Forfeited, Canceled			(66,551	)			89.45		(5,687	)		28.97

	December 31, 2014			261,389				67.89		21,287			22.31

	The following is a summary of outstanding stock options under the Plan as of December 31, 2014:


		Stock Options				Non-Vested Stock
		Outstanding				Options
Quantity			261,389				21,287
Weighted-average exercise price		$	67.89			$	28.97
Weighted Average Remaining Contractual Term (in Years)			6.48				6.3
Intrinsic value		$	—			$	—
For the years ended December 31, 2014, 2013 and 2012, the Company granted 49,550, 45,191 and 56,646 stock options, respectively, with a weighted-average grant date fair value of $7.60, $24.15 and $26.33, respectively. For the years ended December 31, 2014, 2013 and 2012, the total fair value of options vested was $267,382, $887,603 and $1,549,888, respectively. The total intrinsic value of options exercised for the years ended December 31, 2014, 2013 and 2012 was $0, $5,736 and $1,485, respectively.
As of December 31, 2014, total compensation cost not yet recognized related to non-vested stock options was $63,013. The Company expects to recognize this cost over a weighted average period of 0.57 years.

Restructuring

Restructuring	12 Months Ended
Restructuring	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring	8. Restructuring
	On September 30, 2013, we transferred 26 laboratory and pre-clinical employee positions to BBL, an entity then owned in part by our Chief Scientific Officer, or CSO, and director, Dr. Andrei Gudkov, to enable us to better focus on clinical development activities. In connection with this transition, we entered into a Master Services Agreement, or MSA, with BBL, pursuant to which BBL agreed to perform laboratory and pre-clinical research services for us. We plan to engage BBL for pre-clinical research services in the future. Such services are discussed further in Note 9, “Significant Alliances and Related Parties.”
	As a result of the above described restructuring, we recorded $101,000 for one-time employee transition costs, $112,000 for an idle facilities reserve and $293,000 for an impairment loss on research equipment. All of these costs were recorded as R&D expense during the year ended December 31, 2013. During the year ended December 31, 2014, a subsequent measurement adjustment of $33,126 was recorded against our idle facilities reserve.

Significant_Alliances_and_Rela

Significant Alliances and Related Parties	12 Months Ended
Significant Alliances and Related Parties	Dec. 31, 2014
Related Party Transactions [Abstract]
Significant Alliances and Related Parties	9. Significant Alliances and Related Parties
	Roswell Park Cancer Institute
	The Company has entered into several agreements with Roswell Park Cancer Institute, or RPCI, including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase 1 entolimod oncology study and the Phase 1 CBL0137 intravenous administration study. Additionally, the Company’s CSO is the Senior Vice President of Basic Research at RPCI.
	The Company incurred $1,042,859, $2,323,078 and $3,876,073 in expense to RPCI related to research grants and agreements for the years ended December 31, 2014, 2013 and 2012, respectively. The Company had $0 and $172,295 included in accounts payable owed to RPCI at December 31, 2014 and 2013, respectively. In addition, the Company had $324,194 and $491,397 in accrued expenses payable to RPCI at December 31, 2014 and 2013, respectively.
	The Cleveland Clinic
	CBLI entered into an exclusive license agreement, or the License, with The Cleveland Clinic pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates in development by Panacela. CBLI has the primary responsibility to fund all newly developed patents; however, The Cleveland Clinic retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. In consideration for the License, CBLI agreed to issue The Cleveland Clinic common stock and make certain milestone, royalty and sublicense royalty payments. Milestone payments, which may be credited against future royalties, amounted to $0, $0 and $100,000 for the years ended December 31, 2014, 2013 and 2012, respectively. No royalty or sublicense royalty payments were made to The Cleveland Clinic during the three-year period ended December 31, 2014.
	The Company did not have any liabilities to The Cleveland Clinic at December 31, 2014 or 2013.
	Buffalo BioLabs, et. al.
	Our CSO, Dr. Andrei Gudkov has business relationships with several entities with which we transact business, the most significant of which is BBL where Dr. Gudkov was a founder and currently serves as their Principal Scientific Advisor. Pursuant to the MSA that was executed with BBL (see Note 8, “Restructuring”), the Company recognized $1,159,963, $419,284 and $0 as research and development expense for the years ended December 31, 2014, 2013 and 2012, respectively, and included $34,800 and $111,356 in accounts payable at December 31, 2014 and 2013. We also recognized $230,398, $64,362 and $6,500 from BBL for sublease and other income for the years ended December 31, 2014, 2013 and 2012, respectively. Pursuant to our real estate sublease and equipment lease with BBL, we had accounts receivable of $198,124 and $843 at December 31, 2014 and 2013, respectively. As far as other entities with which Dr. Gudkov is affiliated, the Company recognized other income of $0 and $217,347, and $0; and, recognized research and development expenses of $0, $29,607 and $0 for the years ended December 31, 2014, 2013 and 2012, respectively. As of December 31, 2014 and 2013, there were no amounts owed to, or receivable from these entities.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes
	The Company accounts for income taxes using the asset and liability method. Deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets.
	The Company files income tax returns, as prescribed by the national, state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the financial statements when the recognition threshold and measurement attributes are met. Interest and penalties related to tax deficiencies and uncertain tax positions are recorded as income tax expense.
	Income (loss) from continuing operations consists of the following:


			For the Year Ended December 31,
			2014				2013			2012
	US operations		$	6,234,092			$	(13,505,266	)	$	(14,317,608	)
	Foreign operations			(6,198,726	)			(6,624,018	)		(8,097,032	)

			$	35,366			$	(20,129,284	)	$	(22,414,640	)

	The provision for income taxes charged to continuing operations is $0 for all periods presented.
	Deferred tax assets (liabilities) were comprised of the following as of the periods presented below:


			As of December 31,
			2014				2013			2012
	Deferred tax assets:
	Operating loss carryforwards		$	48,643,000			$	44,120,000		$	37,642,000
	Accrued expenses			8,916,000				8,861,000			8,576,000
	Tax credit carryforwards			3,449,000				3,186,000			2,921,000
	Intellectual property			3,214,000				4,846,000			3,377,000
	Outside tax basis difference in affiliate			3,948,000				2,825,000			1,616,000
	Equipment			365,000				388,000			237,000
	Other			—				—			4,000

	Total deferred tax assets			68,535,000				64,226,000			54,373,000
	Deferred tax liabilities:			—				—			—

	Net deferred tax asset			68,535,000				64,226,000			54,373,000
	Valuation allowance			(68,535,000	)			(64,226,000	)		(54,373,000	)

			$	—			$	—		$	—

	The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences:


			For the Year Ended December 31,
			2014				2013			2012
	Tax at the U.S. statutory rate		$	12,000			$	(6,810,000	)	$	(7,621,000	)
	Change in value of warrant liability			(905,000	)			(974,000	)		(2,619,000	)
	Stock option expenses			—				—			—
	Valuation allowance			5,717,000				7,723,000			10,204,000
	Deconsolidation of Incuron			(4,830,000	)
	Other			6,000				61,000			36,000

			$	—			$	—		$	—


	At December 31, 2014, the Company had U.S. federal net operating loss carryforwards of approximately $120,934,000, which begin to expire if not utilized by 2023, and approximately $3,565,000 of tax credit carryforwards which begin to expire if not utilized by 2024. The Company also has U.S. state net operating loss carryforwards of approximately $110,957,000, which begin to expire if not utilized by 2027 and state tax credit carryforwards of approximately $337,000, which begin to expire if not utilized by 2022.
	The Company files U.S. federal tax returns, along with various state and foreign income tax returns. All federal, state and foreign tax returns for the years ended December 31, 2013, 2012 and 2011 are still open for examination.
	The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties:


			Unrecognized				Interest
			Tax Benefits				and Penalties
	Balance at January 1, 2013		$	437,000			$	—

	Prior year tax position			—				—
	Current year tax position			—				—
	Deferred tax position			8,000				—
	Settlements with tax authorities			—				—
Expiration of the statute of limitations			—				—

Balance at December 31, 2013			445,000				—

Prior year tax position			—				—
Current year tax position			—				—
Deferred tax position			8,000				—
Settlements with tax authorities			—				—
Expiration of the statute of limitations			—				—

Balance at December 31, 2014		$	453,000			$	—

CBLI received New York State incentive tax credit refunds of $0, $62,000 and $532,000 during 2014, 2013 and 2012, respectively. These refundable tax credits were based on the Company’s research and development activities, real estate tax payments, employment levels and equipment purchases. Since there is no state tax liability or refund of prior year tax payments, these refundable tax credits were recorded against operating expenses in the year of receipt, instead of being recorded as an income tax benefit.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	11. Employee Benefit Plan
Employee Benefit Plan	CBLI maintains an active defined contribution retirement plan for its employees, referred to herein as the Benefit Plan. All employees satisfying certain service requirements are eligible to participate in the Benefit Plan. The Company makes matching cash contributions each payroll period, up to 4% of employees’ salaries. The Company’s expense relating to the Benefit Plan was $79,737, $196,257 and $201,510 for the years ended December 31, 2014, 2013 and 2012, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies
	The Company has entered into various agreements with third parties and certain related parties in connection with the research and development activities of its existing product candidates as well as discovery efforts on potential new product candidates. These agreements include fixed obligations to sponsor research and development activities and minimum royalty payments for licensed patents. These amounts do not include any additional amounts that the Company may be required to pay under its license agreements upon the achievement of scientific, regulatory and commercial milestones, including milestones such as the submission of an IND to the FDA and the first commercial sale of the Company’s products in various countries. As of December 31, 2014 the Company is uncertain as to whether any of these contingent events will become realized. The Company is also party to five agreements that require it to make milestone payments, pay royalties on net sales of the Company’s products, and make payments on sublicense income received by the Company relating to certain products. There were no milestone payments or royalties on net sales accrued for any of these agreements as of December 31, 2014 and 2013 as none were due.
	From time-to-time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings.
	The Company has entered into agreements with substantially all of our employees who, if terminated by the Company without cause as described in these agreements, would be entitled to severance pay.
	As of December 31, 2014, the Company had unconditional purchase obligations totaling $861,257 for goods and services, substantially all of which the Company anticipates to incur during 2015.
	Capital Lease
	In December 2011, the Company entered into a capital lease for scientific equipment in the amount of $304,673. The terms of the lease required an upfront payment of $82,983 and monthly payments of $7,616 for 36 months once the lease term began in March 2012. Principal payments under the capital lease obligation were $83,634, $78,125 and $52,410; and, interest payments were $7,707, $20,827 and $23,708 for the years ended December 31, 2014, 2013 and 2012, respectively. During the year ended December 31, 2013, the Company recognized an impairment loss of $105,491 related to this leased asset as the anticipated discounted future cash flows resulting from the lease with BBL exceeded the carrying value of the asset. As of December 31, 2014, future minimum lease payments amount to $4,500. As of December 31, 2014, accumulated depreciation for the leased equipment was $27,622.
	Operating Leases
	The Company leases laboratory facilities and office facilities at various locations with expiration dates ranging from 2015 to 2019. The Company recognizes rent expense on a straight-line basis over the term of the related operating leases. For the years ended December 31, 2014, 2013 and 2012, total rent expense related to the Company’s operating leases was $466,770, $511,029 and $459,150, respectively. In addition, the Company has subleased some of its facilities.
	As of December 31, 2014, future minimum payments under operating leases are as follows:


	2015	$	377,623
	2016		354,918
	2017		365,565
	2018		376,532
	2019		191,048

	Total minimum lease payments	$	1,665,686

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
Quarterly Financial Data (Unaudited)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	13. Quarterly Financial Data (Unaudited)

	The following is a summary of the quarterly consolidated results of operations for the years ended December 31, 2014 and December 31, 2013:



		For the Quarter Ended
		March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
	Revenues	$	1,334,254		$	562,087		$	415,126		$	1,390,432
	Loss from Operations		(3,519,062	)		(4,012,504	)		(3,438,739	)		(3,451,630	)
	Net Income (Loss)		(1,901,197	)		(4,131,571	)		(4,615,663	)		10,683,797
	Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(1,585,372	)		(3,961,161	)		(4,096,134	)		11,271,771
	Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.63	)	$	(1.53	)	$	(1.43	)	$	3.95
	Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.63	)	$	(1.53	)	$	(1.43	)	$	3.95
	Weighted Average Shares Outstanding, Basic		2,498,407			2,594,582			2,855,510			2,856,461
	Weighted Average Shares Outstanding, Diluted		2,498,407			2,594,582			2,855,510			2,856,461



		For the Quarter Ended
		31-Mar-13			30-Jun-13			September 30, 2013			December 31, 2013
	Revenues	$	1,367,472		$	1,613,262		$	1,635,600		$	3,871,632
	Loss from Operations		(7,447,515	)		(6,776,618	)		(5,856,468	)		(2,996,158	)
	Net Loss		(10,787,148	)		(3,886,421	)		(4,610,961	)		(844,754	)
	Net Loss Attributable to Cleveland BioLabs, Inc.		(9,764,323	)		(3,042,111	)		(4,091,196	)		(365,247	)
	Basic Loss Per Share Available for Common Shareholders	$	(4.36	)	$	(1.35	)	$	(1.82	)	$	(0.16	)
	Fully Diluted Loss Per Share Available for Common Shareholders	$	(4.36	)	$	(1.35	)	$	(1.82	)	$	(0.16	)
	Weighted Average Shares Outstanding, Basic		2,241,329			2,247,430			2,253,064			2,258,507
	Weighted Average Shares Outstanding, Diluted		2,241,329			2,247,430			2,253,064			2,258,507

Subsequent_Events

Subsequent Events

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Events

14. Subsequent Events

On February 6, 2015, we sold 572,205 shares of common stock, plus an additional 594,688 shares of common stock subject to Series B pre-funded warrants all at a price of $3.00 per share. An additional $717,400 was invested in Series A preferred stock convertible into common stock at $3.00 per share for 239,135 shares and issued in a private placement. The total investment amounted to $4.2 million and the total common shares issuable under these securities are 1,406,028 after full exercise and conversion, subject to shareholder approval. In addition, a total of 1,406,028 Series A warrants to purchase shares of common stock at an exercise price of $3.64 per share were issued in a private placement, which shall be initially exercisable six months following issuance and expire six years from the date they become exercisable.

After giving effect to the forgoing transaction and 5,023 shares issued in January 2015 to certain Board members in lieu of cash compensation, CBLI’s capitalization structure as of February 6, 2015 follows:

Series A convertible preferred stock, $1,000 stated value: 717.4 shares outstanding, convertible into 239,135 common shares. Common shares outstanding: 3,435,354, along with 594,688 shares of common stock issuable under Series B pre-funded warrants. Upon the full conversion of all Series A convertible preferred shares and issuance of stock under all Series B pre-funded warrants, the Company would have 4,269,177 shares of common stock outstanding. All of the common shares issuable under the Series A convertible preferred stock and Series B pre-funded warrants are currently convertible/issuable at $3.00 per share, subject to adjustment if the Company sells stock at a lesser price.

Shares issuable under outstanding options increased since December 31, 2014 and, as of February 6, 2014, there were 261,470 shares issuable at a weighted average price of $67.89 per share.

The following table sets forth the details of our outstanding warrants as of February 6, 2015, giving effect exercise price adjustments triggered by the equity offering discussed above.

Warrant Series

Expiration

Current

Outstanding

Date

Exercise Price

Warrants

Jun 2011 Series F agent

6/17/15

100

8,809

Jan 2014 Series B

7/16/15

24.4

45,291

Jun 2011 Series F

6/22/16

100

73,414

Mar-10

3/2/17

46,771

Oct 2012 Series G

***

10/24/17

215,638

2009 Series D

3/30/18

174,307

Hercules

9/29/18

10.1

7,813

Jan 2014 Series A

1/16/19

24.4

45,291

Jun 2014 Series J

6/20/19

11.2

155,510

Jan 2014 Series A Modified

1/16/21

20.4

102,460

Feb 2015 Series A

8/4/21

3.64

1,406,028

2,281,332

Weighted average exercise price

14.49

can be exercised cashlessly

have price protection only, no increase in shares

***

trade under own cusip

In addition, a warrant for 38,504 shares could be exercised at $33.88 per share in the event of a default on a loan between Rusnano and Panacela. That loan is currently not in default and therefore this warrant is excluded from the above.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation and Consolidation

Use of Estimates

Cash and Cash Equivalents

Short-Term Investments

Concentrations of Credit Risk

As of December 31, 2014, the Company held 43% of its cash and cash equivalents in accounts located outside of the United States.

Significant Customers and Accounts Receivable

Service contract revenue received by us from Incuron accounted for 4.2%, 0.0% and 0.0% of total revenues for the years ended December 31, 2014, 2013 and 2012, respectively.

Equipment

Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:

Asset Category

Estimated Useful Life

(in Years)

Laboratory equipment

Furniture and fixtures

Computer equipment

Impairment of Long-Lived Assets

In connection with the restructuring discussed in Note 8, “Restructuring,” the Company entered into an equipment lease agreement with Buffalo BioLabs, or BBL, effective January 1, 2014 for the equipment used by the employees transitioned to BBL. The estimated fair value of those assets using a discounted cash flow approach was $243,000. Comparing this fair value to the carrying amount of the equipment as of December 31, 2013 of $536,000 resulted in a $293,000 write-down of the assets, which was included in research and development expenses for the year ended December 31, 2013.

Restricted Cash

Equity Method Investments

Equity Method Investment

Intellectual Property

Deferred Revenue

Accrued Warrant Liability

Foreign Currency Translation

Revenue Recognition

Research and Development

Accounting for Stock-Based Compensation

For the year ended December 31,

2014

2013

2012

Risk-free interest rate

1.59 - 1.98

.02 - 1.92

.65 - 1.49

Expected dividend yield

Expected life

5 - 6 Years

5 - 7.3 Years

5 - 6 Years

Expected volatility

71.24 - 78.02

78.62 - 89.66

86.58 - 92.60

“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.

“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

Income Taxes

Income taxes

Earnings (Loss) per Share

Earnings/(loss) per share

The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:

As of December 31,

Common Equivalent Securities

2014

2013

2012

Warrants

875,304

526,752

518,939

Options

261,389

278,242

250,849

Total

1,136,693

804,994

769,788

Comprehensive Income (Loss)

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Property, Plant, and Equipment Useful Lives	Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:


	Asset Category	Estimated Useful Life
	Asset Category	(in Years)

	Laboratory equipment	5
	Furniture and fixtures	5
	Computer equipment	3
Summary of Assumptions Used in Valuing Stock Options Granted	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:



		For the year ended December 31,
		2014			2013			2012
	Risk-free interest rate		1.59 - 1.98	%		.02 - 1.92	%		.65 - 1.49	%
	Expected dividend yield		0	%		0	%		0	%
	Expected life		5 - 6 Years			5 - 7.3 Years			5 - 6 Years
	Expected volatility		71.24 - 78.02	%		78.62 - 89.66	%		86.58 - 92.60	%
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:



		As of December 31,
	Common Equivalent Securities	2014			2013			2012
	Warrants		875,304			526,752			518,939
	Options		261,389			278,242			250,849

	Total		1,136,693			804,994			769,788

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis	The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 and December 31, 2013:


			As of December 31, 2014
			Level 1			Level 2			Level 3		Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	862,074	$	862,074
	Compensatory stock options not yet issued (1)			—			—			132,295		132,295


	Total liabilities		$	—		$	—		$	994,369	$	994,369


			As of December 31, 2013
			Level 1			Level 2			Level 3		Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,241,311	$	1,241,311
	Compensatory stock options not yet issued (1)			—			—			309,450		309,450


	Total liabilities		$	—		$	—		$	1,550,761	$	1,550,761


	-1	Included in accrued expenses in the accompanying consolidated balance sheets.
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	The following are the assumptions used to measure the accrued warrant liability at December 31, 2014 and 2013, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2, “Summary of Significant Accounting Policies”:



			December 31, 2014			December 31, 2013
	Stock Price		$	5.6		$	23.4
	Exercise Price		$	10.10 - 100.00		$	32.00 - 100.00
	Term in years			0.46 - 6.04			0.59 - 1.91
	Volatility			70.69 - 100.08	%		42.52 - 76.03	%
	Annual rate of quarterly dividends			0	%		0	%
	Discount rate- bond equivalent yield			.12 - 1.65	%		.08 - .36	%


Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the year ended December 31, 2014 and 2013:


			Year Ended December 31, 2014
			Accrued Warrant			Compensatory
			Liability			Stock Options
						Issued After Year
						End

	Beginning Balance		$	1,241,311		$	309,450
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(2,572,035	)		(21,055	)
	Issuances			2,283,092			132,295
	Settlements			(90,294	)		(288,395	)


	Balance, December 31, 2014		$	862,074		$	132,295


			Year Ended December 31, 2013
			Accrued Warrant			Compensatory
			Liability			Stock Options
						Issued After Year
						End

	Beginning Balance		$	4,105,659		$	—
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			(2,864,348	)		—
	Estimates and other changes in fair value			—			309,450


	Balance, December 31, 2013		$	1,241,311		$	309,450


	-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. For the year ended December 31, 2014 we realized a gain of $90,294 in connection with the elimination of the Series B warrants issued to an investor in the January 2014 equity investment transaction. For the year ended December 31, 2013 there were no realized gains or losses.
	-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.
Summary of Unobservable Inputs in Fair Value Measurements	The following table summarizes the unobservable inputs into the fair value measurements:


			December 31, 2014
	Description		Fair Value			Valuation Technique		Unobservable Input	Range in years

	Compensatory stock options not yet issued		$	132,295		Black-scholes pricing model		Expected term	5

	Accrued warrant liability			862,074		Black-scholes pricing model		Expected term	0.46 - 6.04


			$	994,369

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2014
Assumptions Used to Measure the Compensatory Stock Options	The following are the assumptions used to measure the compensatory stock options not yet issued at December 31, 2014:


		December 31, 2014

	Stock price	$	5.6
	Term in years		5
	Volatility		73.99	%
	Annual rate of quarterly dividends		0	%
	Discount rate - bond equivalent yield		1.45	%
Schedule of Stockholders' Equity Note, Warrants or Rights	The following table sets forth the changes in the number of warrants outstanding for the periods presented, exclusive of the warrants issued to Rusnano in connection with their loan to Panacela as those warrants are not exercisable until the occurrence of an event of default, which has not occurred:


		Number of			Weighted Average
		Warrants			Exercise Price
	Outstanding at December 31, 2012		518,939		$	58.8
	Granted		7,813			32
	Forfeited, Canceled		—			—

	Outstanding at December 31, 2013		526,752			54
	Granted		451,012			19.85
	Forfeited, Canceled		(102,460	)		24.4

	Outstanding at December 31, 2014		875,304			33.72
Summary of Option Award Activity	The following is a summary of option award activity under the Plan for the year ended December 31, 2014:


		Year Ended December 31, 2014
		Total Stock			Weighted Average		Nonvested Stock			Weighted Average
		Options			Exercise Price per		Options			Grant Date Fair
		Outstanding			Share					Value per Share

	December 31, 2013		278,390		$	82.9		29,724		$	29.97
	Granted		49,550			12.48		2,405			6.73
	Vested		—			—		(5,155	)		51.85
	Exercised		—			—		—			—
	Forfeited, Canceled		(66,551	)		89.45		(5,687	)		28.97


	December 31, 2014		261,389			67.89		21,287			22.31

Summary of Outstanding Stock Options	The following is a summary of outstanding stock options under the Plan as of December 31, 2014:


		Stock			Non-Vested Stock
		Options			Options
		Outstanding

	Quantity		261,389			21,287
	Weighted-average exercise price	$	67.89		$	28.97
	Weighted Average Remaining Contractual Term (in Years)		6.48			6.3
	Intrinsic value	$	—		$	—
Pre-Funded Warrants [Member]
Assumptions Used to Measure the Compensatory Stock Options	The fair value of the January Series A and B warrants amounted to $2,283,092 and was determined based on the following assumptions using the Black-Scholes valuation model:


		January 16,
		2014
	Stock price	$	24.6
	Exercise price	$	24.4
	Term in years		.75 - 2.50
	Expected volatility		43.06 - 79.86	%
	Expected dividend yield		0	%
	Risk-free interest rate		.09 - .58	%
	Certain warrants issued during the 2012 offering contain provisions that could require the Company to settle the warrants in cash and, accordingly, were originally recorded as a liability in the amount of $4,521,681 determined by the Black-Scholes valuation model with the following assumptions:


	Stock price	$	49.6
	Exercise price	$	60
	Term in years		2.51
	Expected volatility		79.7	%
	Expected dividend yield		0	%
	Risk-free interest rate		0.35	%

Equipment_Tables

Equipment (Tables)	12 Months Ended
Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Summary of Equipment Costs	The following table summarizes the Company’s gross equipment costs for the years ended December 31, 2014 and 2013:


		As of December 31,
		2014			2013

	Lab equipment	$	1,062,679		$	1,083,463
	Computer equipment		293,663			332,386
	Furniture		528,807			528,807

			1,885,149			1,944,656
	Less accumulated depreciation		(1,640,612	)		(1,486,744	)


	Equipment, net	$	244,537		$	457,912

Noncontrolling_Interests_Table

Noncontrolling Interests (Tables)	12 Months Ended
Noncontrolling Interests (Tables)	Dec. 31, 2014
Noncontrolling Interest [Abstract]
Summary of Incuron's Financial Position	A summary of Incuron’s financial position and results of operations follows:


	December 31, 2014
	ASSETS				LIABILITIES AND EQUITY
	Cash and cash equivalents	$	1,103,384		Accounts payable	$	33,303
	Short-term investments		248,852		Accounts payable to CBLI		156,464
	Other current assets		47,846		Accrued expenses		253,915

	Total current assets		1,400,082		Total current liabilities		443,681
	Long-term assets		6,900		Net equity		963,300

	Total assets	$	1,406,982		Total liabilities and equity	$	1,406,982
Summary of Incuron's Results of Operations	STATEMENT OF OPERATIONS
	For the period from
	November 26, 2014 to December 31, 2014

	REVENUES
	Grant and contract revenue	$	—
	OPERATING EXPENSES
	Research and development		215,392
	CBLI development costs		169,511
	General and administrative		106,277

	Total operating expenses		491,180

	LOSS FROM OPERATIONS		(491,180	)
	OTHER EXPENSES
	Foreign exchange gain (loss)		(116,874	)

	NET INCOME/(LOSS)	$	(608,054	)

Debt_Tables

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2014
Debt Disclosure [Abstract]
Summary of Principal Payments	The following schedule shows the payments for principal and the end of term charge on the Hercules loan by calendar year:


	2015	$	748,738
	2016		831,721
	2017		852,365

	Total	$	2,432,824

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign	Income (loss) from continuing operations consists of the following:



		For the Year Ended December 31,
		2014			2013			2012
	US operations	$	6,234,092		$	(13,505,266	)	$	(14,317,608	)
	Foreign operations		(6,198,726	)		(6,624,018	)		(8,097,032	)

		$	35,366		$	(20,129,284	)	$	(22,414,640	)

Schedule of Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) were comprised of the following as of the periods presented below:



		As of December 31,
		2014			2013			2012
	Deferred tax assets:
	Operating loss carryforwards	$	48,643,000		$	44,120,000		$	37,642,000
	Accrued expenses		8,916,000			8,861,000			8,576,000
	Tax credit carryforwards		3,449,000			3,186,000			2,921,000
	Intellectual property		3,214,000			4,846,000			3,377,000
	Outside tax basis difference in affiliate		3,948,000			2,825,000			1,616,000
	Equipment		365,000			388,000			237,000
	Other		—			—			4,000

	Total deferred tax assets		68,535,000			64,226,000			54,373,000
	Deferred tax liabilities:		—			—			—

	Net deferred tax asset		68,535,000			64,226,000			54,373,000
	Valuation allowance		(68,535,000	)		(64,226,000	)		(54,373,000	)

		$	—		$	—		$	—

Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences:



		For the Year Ended December 31,
		2014			2013			2012
	Tax at the U.S. statutory rate	$	12,000		$	(6,810,000	)	$	(7,621,000	)
	Change in value of warrant liability		(905,000	)		(974,000	)		(2,619,000	)
	Stock option expenses		—			—			—
	Valuation allowance		5,717,000			7,723,000			10,204,000
	Deconsolidation of Incuron		(4,830,000	)
	Other		6,000			61,000			36,000

		$	—		$	—		$	—

Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties	The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties:



		Unrecognized			Interest
		Tax Benefits			and Penalties
	Balance at January 1, 2013	$	437,000		$	—

	Prior year tax position		—			—
	Current year tax position		—			—
	Deferred tax position		8,000			—
	Settlements with tax authorities		—			—
	Expiration of the statute of limitations		—			—

	Balance at December 31, 2013		445,000			—

	Prior year tax position		—			—
	Current year tax position		—			—
	Deferred tax position		8,000			—
	Settlements with tax authorities		—			—
	Expiration of the statute of limitations		—			—

	Balance at December 31, 2014	$	453,000		$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Operating Leases	As of December 31, 2014, future minimum payments under operating leases are as follows:



	2015	$	377,623
	2016		354,918
	2017		365,565
	2018		376,532
	2019		191,048

	Total minimum lease payments	$	1,665,686

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
Quarterly Financial Data (Unaudited) (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of the Quarterly Consolidated Results of Operations	The following is a summary of the quarterly consolidated results of operations for the years ended December 31, 2014 and December 31, 2013:



		For the Quarter Ended
		March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
	Revenues	$	1,334,254		$	562,087		$	415,126		$	1,390,432
	Loss from Operations		(3,519,062	)		(4,012,504	)		(3,438,739	)		(3,451,630	)
	Net Income (Loss)		(1,901,197	)		(4,131,571	)		(4,615,663	)		10,683,797
	Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(1,585,372	)		(3,961,161	)		(4,096,134	)		11,271,771
	Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.63	)	$	(1.53	)	$	(1.43	)	$	3.95
	Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.63	)	$	(1.53	)	$	(1.43	)	$	3.95
	Weighted Average Shares Outstanding, Basic		2,498,407			2,594,582			2,855,510			2,856,461
	Weighted Average Shares Outstanding, Diluted		2,498,407			2,594,582			2,855,510			2,856,461



		For the Quarter Ended
		31-Mar-13			30-Jun-13			September 30, 2013			December 31, 2013
	Revenues	$	1,367,472		$	1,613,262		$	1,635,600		$	3,871,632
	Loss from Operations		(7,447,515	)		(6,776,618	)		(5,856,468	)		(2,996,158	)
	Net Loss		(10,787,148	)		(3,886,421	)		(4,610,961	)		(844,754	)
	Net Loss Attributable to Cleveland BioLabs, Inc.		(9,764,323	)		(3,042,111	)		(4,091,196	)		(365,247	)
	Basic Loss Per Share Available for Common Shareholders	$	(4.36	)	$	(1.35	)	$	(1.82	)	$	(0.16	)
	Fully Diluted Loss Per Share Available for Common Shareholders	$	(4.36	)	$	(1.35	)	$	(1.82	)	$	(0.16	)
	Weighted Average Shares Outstanding, Basic		2,241,329			2,247,430			2,253,064			2,258,507
	Weighted Average Shares Outstanding, Diluted		2,241,329			2,247,430			2,253,064			2,258,507

Subsequent_Events_Tables

Subsequent Events (Tables)

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Summary of outstanding warrants

The following table sets forth the details of our outstanding warrants as of February 6, 2015, giving effect exercise price adjustments triggered by the equity offering discussed above.

Warrant Series

Expiration

Current

Outstanding

Date

Exercise Price

Warrants

Jun 2011 Series F agent

6/17/15

100

8,809

Jan 2014 Series B

7/16/15

24.4

45,291

Jun 2011 Series F

6/22/16

100

73,414

Mar-10

3/2/17

46,771

Oct 2012 Series G

***

10/24/17

215,638

2009 Series D

3/30/18

174,307

Hercules

9/29/18

10.1

7,813

Jan 2014 Series A

1/16/19

24.4

45,291

Jun 2014 Series J

6/20/19

11.2

155,510

Jan 2014 Series A Modified

1/16/21

20.4

102,460

Feb 2015 Series A

8/4/21

3.64

1,406,028

2,281,332

Weighted average exercise price

14.49

can be exercised cashlessly

have price protection only, no increase in shares

***

trade under own cusip

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
	Subsidiary
Subsidiary or Equity Method Investee [Line Items]
Number of collaboration with financial partners	2
BioLab 612 [Member]
Subsidiary or Equity Method Investee [Line Items]
Number Of wholly-owned subsidiaries	1
Incuron, LLC and Panacela Labs, Inc. [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of majority owned subsidiaries	1
Incuron, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of unconsolidated joint venture	1

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 12, 2015	Jan. 28, 2015	Nov. 25, 2014	Dec. 31, 2011	Feb. 06, 2015
	Agreement	Dec. 31, 2013	Dec. 31, 2012	Feb. 12, 2015	Jan. 28, 2015	Nov. 25, 2014	Dec. 31, 2011	Feb. 06, 2015
Accounting Policies [Line Items]
Cash and cash equivalents at carrying value	$3,103,969	$10,048,466	$25,652,083				$22,872,589
General use cash total	2,600,000
Other cash and cash equivalents at carrying value	0	3,500,000
Cash and highly liquid investments maturity	90 days
Decrease in cash & cash equivalents	-6,944,497	-15,603,617	2,779,494
Allowances for doubtful accounts	0.1	0
Carrying amount of the equipment	536,000
Fair value of assets	243,000
Write-down of the assets	293,000	293,000
Equity method investment	4,268,458					4,554,000
Number of contractual arrangement	2
Share-based compensation arrangement by share-based payment award, number of shares authorized	500,000
Share-based compensation arrangement by share-based payment award, number of shares available for grant	100,000
Share-based compensation arrangement by share-based payment award number of shares limited per year	20,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, outstanding, weighted average remaining contractual terms	10 years
Income tax expense	0	0	0
2013 ESPP Plan [Member]
Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant	115,000
Percentage of the total number of shares of common stock outstanding of the preceding year	10.00%
Share-based compensation arrangement by share-based payment award, number of shares limited per year	10,000
Share-based compensation arrangement by share-based payment award, maximum employee subscription rate	15.00%
Share-based compensation arrangement by share-based payment award, discount from market price, offering rate	85.00%
Employee maximum yearly contribution	25,000
Buffalo BioLabs [Member]
Accounting Policies [Line Items]
Date of equipment lease agreement	1-Jan-14
Certificates of Deposit [Member]
Accounting Policies [Line Items]
Short-term investments	0	300,000
Subsequent Event [Member]
Accounting Policies [Line Items]
Reverse split of common stock					On January 28, 2015 the Company, after receiving authorization from the Company's shareholders and board of directors, executed a reverse split of the Company's common stock at the ratio of 120.
Cash and cash equivalents at carrying value								6,800,000
General use cash total								6,300,000
Decrease in cash & cash equivalents				200,000
Accounts Receivable [Member]
Accounting Policies [Line Items]
Credit term	30 days
Customer Concentration Risk [Member] \| Sales Revenue, Services, Net [Member] \| Incuron, LLC [Member]
Accounting Policies [Line Items]
Concentration risk percentage	4.20%	0.00%	0.00%
UNITED STATES \| Government Contracts Concentration Risk [Member] \| Sales Revenue, Services, Net [Member]
Accounting Policies [Line Items]
Concentration risk percentage	0.60%	26.80%	34.80%
RUSSIAN FEDERATION \| Government Contracts Concentration Risk [Member] \| Sales Revenue, Services, Net [Member]
Accounting Policies [Line Items]
Concentration risk percentage	95.20%	73.20%	65.20%
Minimum [Member]
Accounting Policies [Line Items]
Exchange rate	$56.26
Minimum [Member] \| Certificates of Deposit [Member]
Accounting Policies [Line Items]
Short-term investments maturity	3 months
Maximum [Member] \| Subsequent Event [Member]
Accounting Policies [Line Items]
Exchange rate				$66.06
Panacela [Member]
Accounting Policies [Line Items]
Restricted cash and cash equivalents	500,000
Panacela [Member]
Accounting Policies [Line Items]
Restricted cash and cash equivalents	$500,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Property, Plant,and Equipment Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2014
Laboratory Equipment [Member]
Accounting Policies [Line Items]
Assets, Estimated useful life	5 years
Furniture and Fixtures [Member]
Accounting Policies [Line Items]
Assets, Estimated useful life	5 years
Computer Equipment [Member]
Accounting Policies [Line Items]
Assets, Estimated useful life	3 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Assumptions Used in Valuing Stock Options Granted (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.45%
Expected dividend yield	0.00%	0.00%
Expected life	5 years
Expected volatility	73.99%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.12%	0.08%
Expected life	5 months 16 days	7 months 2 days
Expected volatility	70.69%	42.52%
Minimum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.59%	0.02%	0.65%
Expected life	5 years	5 years	5 years
Expected volatility	71.24%	78.62%	86.58%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.65%	0.36%
Expected life	6 years 15 days	1 year 10 months 28 days
Expected volatility	100.08%	76.03%
Maximum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.98%	1.92%	1.49%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	6 years	7 years 3 months 18 days	6 years
Expected volatility	78.02%	89.66%	92.60%

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,136,693	804,994	769,788
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	875,304	526,752	518,939
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	261,389	278,242	250,849

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Liabilities:
Accrued warrant liability	$862,074	$1,241,311
Compensatory stock options not yet issued	132,295	309,450
Total liabilities	994,369	1,550,761
Level 3 [Member]
Liabilities:
Accrued warrant liability	862,074	1,241,311
Compensatory stock options not yet issued	132,295	309,450
Total liabilities	$994,369	$1,550,761

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 20, 2014	Jan. 16, 2014	Oct. 31, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$5.60	$23.40	$11.35	$24.40	$40
Term in years	5 years
Volatility	73.99%
Annual rate of quarterly dividends	0.00%	0.00%
Discount rate-bond equivalent yield	1.45%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$10.10	$32
Term in years	5 months 16 days	7 months 2 days
Volatility	70.69%	42.52%
Discount rate-bond equivalent yield	0.12%	0.08%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$100	$100
Term in years	6 years 15 days	1 year 10 months 28 days
Volatility	100.08%	76.03%
Discount rate-bond equivalent yield	1.65%	0.36%

Fair_Value_Measurements_Assump

Fair Value Measurements - Assumptions Used to Measure the Compensatory Stock Options (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 20, 2014	Jan. 16, 2014	Oct. 31, 2012
Debt Instrument Fair Value Carrying Value [Abstract]
Stock price	$5.60	$23.40	$11.35	$24.40	$40
Term in years	5 years
Volatility	73.99%
Annual rate of quarterly dividends	0.00%	0.00%
Discount rate - bond equivalent yield	1.45%

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Ending balance	$994,369
Assets or liabilities	0	0
Accrued Warrant Liability [Member]
Beginning balance	1,241,311	4,105,659
Total (gains) or losses, realized and unrealized, included in earnings	-2,572,035	-2,864,348
Issuances	2,283,092
Settlements	-90,294
Ending balance	862,074	1,241,311
Increase in expected term	10.00%
Increase in accrued warrant liability with increase in expected term	13.00%
Decrease in expected term	10.00%
Decrease in accrued warrant liability with decrease in expected term	14.00%
Increase in stock price	10.00%
Increase in accrued warrant liability with increase in stock price	17.00%
Decrease in stock price	10.00%
Decrease in accrued warrant liability with decrease in stock price	16.00%
Compensatory Stock Options Not Yet Issued [Member]
Beginning balance	309,450
Total (gains) or losses, realized and unrealized, included in earnings	-21,055
Issuances	132,295
Settlements	-288,395
Ending balance	132,295	309,450
Estimates and other changes in fair value		$309,450
Increase or decrease in expected term	10.00%
Increase or decrease in amount accrued with expected term change	4.00%
Increase or decrease in stock price	10.00%
Increase or decrease in amount accrued with stock price change	10.00%

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Parenthetical) (Detail) (Series B Warrants [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Series B Warrants [Member]
Realized gains or losses	$90,294	$0

Fair_Value_Measurements_Summar2

Fair Value Measurements - Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	$994,369
Compensatory Stock Options Not Yet Issued [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	132,295	309,450
Valuation Technique	Black-scholes pricing model
Unobservable Input	Expected term
Accrued Warrant Liability [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	$862,074	$1,241,311	$4,105,659
Valuation Technique	Black-scholes pricing model
Unobservable Input	Expected term
Minimum [Member] \| Accrued Warrant Liability [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	5 months 16 days
Maximum [Member] \| Compensatory Stock Options Not Yet Issued [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	5 years
Maximum [Member] \| Accrued Warrant Liability [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	6 years 15 days

Equipment_Summary_of_Equipment

Equipment - Summary of Equipment Costs (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$1,885,149	$1,944,656
Less accumulated depreciation	-1,640,612	-1,486,744
Equipment, net	244,537	457,912
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	1,062,679	1,083,463
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	293,663	332,386
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$528,807	$528,807

Equipment_Additional_Informati

Equipment - Additional Information (Detail) (USD $)	12 Months Ended
Equipment - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Cost of equipment	$1,885,149	$1,944,656
Net book value of equipment	244,537	457,912
Buffalo BioLabs [Member]
Property, Plant and Equipment [Line Items]
Cost of equipment	1,054,166
Net book value of equipment	137,553
Buffalo BioLabs [Member] \| Equipment [Member]
Property, Plant and Equipment [Line Items]
Monthly income from lease equipment	$4,500
Lease cancellable notice period	90 days

Noncontrolling_Interests_Addit

Noncontrolling Interests - Additional Information (Detail)

0 Months Ended

12 Months Ended

0 Months Ended

Nov. 25, 2014

Jun. 21, 2014

Jun. 20, 2014

Oct. 31, 2011

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Nov. 25, 2014

Dec. 31, 2014

Nov. 25, 2014

31-May-12

Dec. 31, 2014

Oct. 31, 2011

Dec. 31, 2014

Sep. 03, 2014

Oct. 31, 2011

Aug. 05, 2014

Jun. 20, 2014

31-May-12

Nov. 25, 2014

Aug. 06, 2014

Aug. 05, 2014

Jun. 21, 2014

Jun. 20, 2014

31-May-12

USD ($)

Incuron, LLC [Member]

Rusnano [Member]

Bioprocess Capital Ventures [Member]

USD ($)

Market Approach Valuation Technique [Member]

Income Approach Valuation Technique [Member]

USD ($)

Panacela [Member]

Incuron, LLC [Member]

Level 3 [Member]

USD ($)

RUB

USD ($)

RUB

USD ($)

RUB

Noncontrolling Interest [Line Items]

Payments to acquire additional interest in subsidiaries

$17,000,000

$2,300,000

79,900,000

$2,900,000

100,000,000

$5,900,000

194,000,000

Noncontrolling interest, ownership percentage by noncontrolling owners

57.78%

3.05%

49.98%

46.06%

40.78%

Equity ownership percentage

46.96%

59.22%

Ownership interest in Incuron, LLC majority-owned subsidiary

53.94%

59.22%

Revenue

1,000,770

General and administrative expense

1,664,094

9,654,144

19,525,950

22,501,805

Research and development expense

907,643

8,469,690

12,038,775

11,115,511

Equity method investment losses

285,542

Gain on deconsolidation

14,206,555

Retained investment in Incuron

4,268,458

4,554,000

Non-controlling interest on deconsolidation

9,797,083

11,396,710

Carrying amount of net assets

144,528

Weights used in calculating risk adjusted debt-free discounted cash flow for determining fair value of Incuron, Market approach

50.00%

Weights used in calculating risk adjusted debt-free discounted cash flow for determining fair value of Incuron, Income approach

50.00%

Unobservable input of the market approach as a multiple of market value to invested capital

0.5

Unobservable input to the income approach, based on discount rate based upon a weighted average cost of capital

22.00%

Recognized revenues associated with executed services contract

154,687

Accounts receivable with Incuron

156,464

Payments to Acquire Interest in Subsidiaries and Affiliates (in Dollars)

3,000,000

9,000,000

Debt Instrument, Face Amount

1,500,000

Amount available to be invested at option

$15,500,000

Noncontrolling_Interests_Summa

Noncontrolling Interests - Summary of Incuron's Financial Position (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
ASSETS
Cash and cash equivalents	$3,103,969	$10,048,466	$25,652,083	$22,872,589
Other current assets	174,179	344,386
Total current assets	3,545,347	11,156,781
Total assets	9,814,232	14,695,641
LIABILITIES AND EQUITY
Accounts payable	1,057,743	794,397
Accrued expenses	1,804,456	2,445,446
Total current liabilities	6,529,080	5,985,753
Net equity	-1,607,397	-9,522,945
Total liabilities and stockholders' equity	9,814,232	14,695,641
Incuron [Member]
ASSETS
Cash and cash equivalents	1,103,384
Short-term investments	248,852
Other current assets	47,846
Total current assets	1,400,082
Long-term assets	6,900
Total assets	1,406,982
LIABILITIES AND EQUITY
Accounts payable	33,303
Accounts payable to CBLI	156,464
Accrued expenses	253,915
Total current liabilities	443,681
Net equity	963,300
Total liabilities and stockholders' equity	$1,406,982

Noncontrolling_Interests_Summa1

Noncontrolling Interests - Summary of Incuron's Results of Operations (Detail) (USD $)	0 Months Ended	3 Months Ended								12 Months Ended			1 Months Ended
	Nov. 25, 2014	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
OPERATING EXPENSES
Research and development	$1,664,094									$9,654,144	$19,525,950	$22,501,805
General and administrative	907,643									8,469,690	12,038,775	11,115,511
Total operating expenses										18,123,834	31,564,725	33,617,316
Loss from operations		-3,451,630	-3,438,739	-4,012,504	-3,519,062	-2,996,158	-5,856,468	-6,776,618	-7,447,515	-14,421,935	-23,076,759	-30,046,606
OTHER EXPENSES
Foreign exchange gain (loss)										-1,036,459	38,202	-365,138
Net income (loss)		10,683,797	-4,615,663	-4,131,571	-1,901,197	-844,754	-4,610,961	-3,886,421	-10,787,148	35,366	-20,129,284	-22,414,640
Incuron [Member]
REVENUES
Grant and contract revenue													0
OPERATING EXPENSES
Research and development													215,392
CBLI development costs													169,511
General and administrative													106,277
Total operating expenses													491,180
Loss from operations													-491,180
OTHER EXPENSES
Foreign exchange gain (loss)													-116,874
Net income (loss)													($608,054)

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended		1 Months Ended
Debt - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 20, 2014	Jan. 16, 2014	Oct. 31, 2012
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)					$10.10	$24.40	$40
Panacela Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$1,530,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)		$33.88
Debt Instrument, interest Rate, stated percentage	16.30%
Accrued Interest	355,493
Debt Instrument, Convertible, Conversion Price (in Dollars per Share	$1,057
Debt Instrument, Convertible, Beneficial Conversion Feature	0.75
Debt Instrument, Assignment Percentage		69.20%
Interest expense		1,340,639	338,112
Non cash write off, debt issuance cost		401,803
Early repayment of debt		4,000,000
Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
Debt instrument, Description of variable Rate Basis	Prime
Debt Instrument, Face Amount	6,000,000
Proceeds from Notes Payable	5,900,000
Debt Instrument, Interest Rate, Stated Percentage rate Range, Minimum	10.45%
Debt Instrument, Basis Spread on variable rate	4.25%
Net proceeds from sale of equity and cash				4,000,000
Legal fees		102,000
Facility fees		100,000
End of term charge,		550,000
Warrant term		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		7,813
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)		$32
Fair value of warrants issued in connection with debt		$117,999
Debt Instrument, Interest rate, Effective Percentage		16.60%
Hercules Technology II, L.P. [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument Penalty rate		1.00%
Hercules Technology II, L.P. [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument Penalty rate		3.00%
Hercules Technology II, L.P. [Member] \| Interest- Only Payments [Member]
Debt Instrument [Line Items]
Debt Instrument, Frequency of Periodic Payment		12
Hercules Technology II, L.P. [Member] \| Principle and Interest Payments [Member]
Debt Instrument [Line Items]
Debt Instrument, Frequency of Periodic Payment		27

Debt_Summary_of_Principal_Paym

Debt - Summary of Principal Payments (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Total	$1,499,050	$7,121,388
Hercules Technology II, L.P. and Rusnano [Member] \| Hercules Technology II, L.P. [Member]
Debt Instrument [Line Items]
2015	748,738
2016	831,721
2017	852,365
Total	$2,432,824

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	12 Months Ended			0 Months Ended
	Jun. 20, 2014	Jan. 16, 2014	Oct. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 04, 2014	Jan. 27, 2015	Sep. 29, 2014	Feb. 06, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued in public offering	308,370	286,886	51,250
Number of warrants issued	154,186		28,125
Common stock at a price	$11.35	$24.40	$40	$5.60	$23.40
Proceeds from Issuance of Common Stock	$3,300,000	$6,400,000		$9,697,501		$15,675,727
Number of warrants adjusted due to reduction in exercise price	228,891	221,078
Exercise Price of warrants	$10.10	$24.40	$40
Number of units in public offering			187,500
Number of common stock shares for each unit			1
Underwriters option, days to exercise			30 days
Warrants not settleable in cash, fair value disclosure			4,521,681
Number of warrants outstanding			46,771
Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures				49,550	45,191	56,646
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted-average grant date fair value				$7.60	$24.15	$26.33
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value				267,382	887,603	1,549,888
Share-based compensation arrangement by share-based payment award, options, exercises in period, total intrinsic value				0	5,736	1,485
Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized				63,013
Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized, period for recognition				6 months 26 days
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued in public offering				595,256		426,250
Class of warrant or right, number of securities called by each warrant or right			0.5
Class of warrant or right, number of securities called by warrants or rights			56,250
Over-allotment price per share			$39.90
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price of warrants				$33.72	$54	$58.80
Number of warrants for each shares of common stock			1
Class of warrant or right, number of securities called by warrants or rights			28,125
Over-allotment price per warrant to purchase a whole share			0.19
Number of warrants outstanding				875,304	526,752	518,939
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock exercise price, maximum							$20.40
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock exercise price, maximum							$24.40
Per Whole Share [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price of warrants			$60
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock split ratio								20
Exercise Price of warrants										$14.49
Number of warrants outstanding										2,281,332
Series A Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares , repurchase							102,460
Warrant or Right, Date from which Warrants or Rights Exercisable									16-Jan-21
Series A Warrants [Member] \| Accrued Warrant Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants				2,283,092
Series A Warrants [Member] \| Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price of warrants										$3.64
Series B Warrants [Member] \| Accrued Warrant Liability [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants				$2,283,092
Series B Pre-funded Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares , repurchase							102,460
Series D Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares , repurchase									174,307
Warrant or Right, Date from which Warrants or Rights Exercisable									30-Mar-18
Purchasers [Member] \| Series A Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued		143,445
Warrants exercisable price per share		$24.40
Warrants expiration period from the date of issuance		5 years
Warrants exercisable period from the date of issuance		9 months
Purchasers [Member] \| Series B Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued		143,445
Warrants exercisable price per share		$24.40
Warrants expiration period from the date of issuance		18 months
Warrants exercisable period from the date of issuance		9 months
Purchasers [Member] \| Series J [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued	154,186
Warrants exercisable price per share	$11.20
Warrants expiration period from the date of issuance	5 years
Placement Agent [Member] \| Series A Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued		4,306
Placement Agent [Member] \| Series B Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued		4,306
Placement Agent [Member] \| Series J [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued	1,324
Warrants exercisable price per share	$11.20
Warrants expiration period from the date of issuance	5 years

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Assumptions Used in Valuing Stock Options Granted (Detail) (USD $)	12 Months Ended		0 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jan. 16, 2014	Oct. 31, 2012	Jun. 20, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price	$5.60	$23.40	$24.40	$40	$11.35
Term in years	5 years
Expected volatility	73.99%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.45%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$10.10	$32
Term in years	5 months 16 days	7 months 2 days
Expected volatility	70.69%	42.52%
Risk-free interest rate	0.12%	0.08%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$100	$100
Term in years	6 years 15 days	1 year 10 months 28 days
Expected volatility	100.08%	76.03%
Risk-free interest rate	1.65%	0.36%
Black Scholes Stock Price Valuation Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price			$24.60	$49.60
Exercise price			$24.60	$60
Term in years				2 years 6 months 4 days
Expected volatility				79.70%
Expected dividend yield			0.00%	0.00%
Risk-free interest rate				0.35%
Black Scholes Stock Price Valuation Model [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years			9 months
Expected volatility			43.06%
Risk-free interest rate			0.09%
Black Scholes Stock Price Valuation Model [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years			2 years 6 months
Expected volatility			79.86%
Risk-free interest rate			0.58%

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 20, 2014	Jan. 16, 2014	Oct. 31, 2012
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding, Beginning balance					46,771
Number of Warrants Outstanding, Ending balance					46,771
Weighted Average Exercise Price, Outstanding, Beginning balance			$10.10	$24.40	$40
Weighted Average Exercise Price, Outstanding, Ending balance			$10.10	$24.40	$40
Warrants [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding, Beginning balance	526,752	518,939
Number of Warrants, Granted	451,012	7,813
Number of Warrants, Forfeited, Canceled	-102,460	0
Number of Warrants Outstanding, Ending balance	875,304	526,752
Weighted Average Exercise Price, Outstanding, Beginning balance	$54	$58.80
Weighted Average Exercise Price, Granted	$19.85	$32
Weighted Average Exercise Price, Forfeited, Canceled	$24.40	$0
Weighted Average Exercise Price, Outstanding, Ending balance	$33.72	$54

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Option Award Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]
Total Stock Options Outstanding, Beginning balance	278,390
Total Stock Options Outstanding, Granted	49,550	45,191	56,646
Total Stock Options Outstanding, Vested
Total Stock Options Outstanding, Exercised
Total Stock Options Outstanding, Forfeited, Canceled	-66,551
Total Stock Options Outstanding, Ending balance	261,389	278,390
Weighted Average Exercise Price per Share, Beginning balance	$82.90
Weighted Average Exercise Price per Share, Granted	$12.48
Weighted Average Exercise Price per Share, Vested
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited, Canceled	$89.45
Weighted Average Exercise Price per Share, Ending balance	$67.89	$82.90
Nonvested Stock Options, Beginning balance	29,724
Nonvested Stock Options, Granted	2,405
Nonvested Stock Options, Vested	-5,155
Nonvested Stock Options, Exercised
Nonvested Stock Options, Forfeited, Canceled	-5,687
Nonvested Stock Options, Ending balance	21,287	29,724
Weighted Average Grant Date Fair Value per Share, Beginning balance	$29.97
Weighted Average Grant Date Fair Value per Share, Granted	$6.73
Weighted Average Grant Date Fair Value per Share, Vested	$51.85
Weighted Average Grant Date Fair Value per Share, Exercised
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled	$28.97
Weighted Average Grant Date Fair Value per Share, Ending balance	$22.31	$29.97

Stockholders_Equity_Summary_of2

Stockholders' Equity - Summary of Outstanding Stock Options (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Feb. 06, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity	261,389	278,390
Stock Options Outstanding, Weighted-average exercise price	$67.89	$82.90
Vested Stock Options, Quantity	21,287	29,724
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity	261,389		261,470
Stock Options Outstanding, Weighted-average exercise price	$67.89
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	6 years 5 months 23 days
Stock Options Outstanding, Intrinsic value
Vested Stock Options, Quantity	21,287
Vested Stock Options, Weighted-average exercise price	$28.97
Vested Stock Options, Weighted Average Remaining Contractual Term (in Years)	6 years 3 months 18 days
Vested Stock Options, Intrinsic value

Restructuring_Additional_infor

Restructuring - Additional information (Detail) (USD $)	12 Months Ended
Restructuring - Additional information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Facilities reserve	$33,126
Write-down of the assets	293,000	293,000
One-Time Employee Transition Costs [Member]
Employee transition costs		101,000
Other Restructuring [Member]
Facilities reserve		$112,000

Significant_Alliances_and_Rela1

Significant Alliances and Related Parties - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Nov. 25, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Research and development expense	$1,664,094	$9,654,144	$19,525,950	$22,501,805
Accounts payable owed		1,057,743	794,397
R P C I [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party		1,042,859	2,323,078	3,876,073
Accounts payable owed		0	172,295
Due to related parties, current		324,194	491,397
Entities Affiliated with Consultant [Member]
Related Party Transaction [Line Items]
Revenue from related parties		230,398	64,362	6,500
Research and development expense		1,159,963	419,284	6,500
Accounts payable owed		0
Entities Affiliated with Consultant [Member] \| Other Income [Member]
Related Party Transaction [Line Items]
Revenue from related parties		0	217,347	0
Buffalo BioLabs [Member]
Related Party Transaction [Line Items]
Accounts payable owed		34,800	111,356
Revenue from related parties		0	217,347	0
Research and development expense		0	29,607	0
Sublease revenue receivable		198,124	843
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction		0	0	100,000
Royalty or sublicense royalty payments		$0	$0	$0

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
US operations	$6,234,092	($13,505,266)	($14,317,608)
Foreign operations	-6,198,726	-6,624,018	-8,097,032
Total	$35,366	($20,129,284)	($22,414,640)

Income_Taxes_Additional_inform

Income Taxes - Additional information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Income tax expense (benefit), continuing operations	$0	$0	$0
Deferred tax assets, tax credit carryforwards	3,449,000	3,186,000	2,921,000
NEW YORK
Income Tax Disclosure [Line Items]
Proceeds from income tax refunds	0	62,000	532,000
Expire 2023 [Member]
Income Tax Disclosure [Line Items]
Deferred tax assets, operating loss carryforwards, domestic	120,934,000
Deferred tax assets, tax credit carryforwards	3,565,000
Expire 2027 [Member]
Income Tax Disclosure [Line Items]
Deferred tax assets, operating loss carryforwards, state and local	110,957,000
Expire 2022 [Member]
Income Tax Disclosure [Line Items]
Deferred tax assets, operating loss carryforwards, domestic	$337,000

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:
Operating loss carryforwards	$48,643,000	$44,120,000	$37,642,000
Accrued expenses	8,916,000	8,861,000	8,576,000
Tax credit carryforwards	3,449,000	3,186,000	2,921,000
Intellectual property	3,214,000	4,846,000	3,377,000
Outside tax basis difference in affiliate	3,948,000	2,825,000	1,616,000
Equipment	365,000	388,000	237,000
Other			4,000
Total deferred tax assets	68,535,000	64,226,000	54,373,000
Deferred tax liabilities
Net deferred tax asset	68,535,000	64,226,000	54,373,000
Valuation allowance	-68,535,000	-64,226,000	-54,373,000
Total deferred tax assets (liabilities)	$0	$0	$0

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Tax at the U.S. statutory rate	$12,000	($6,810,000)	($7,621,000)
Change in value of warrant liability	-905,000	-974,000	-2,619,000
Stock option expenses	0	0	0
Valuation allowance	5,717,000	7,723,000	10,204,000
Deconsolidation of Incuron	-4,830,000
Other	6,000	61,000	36,000
Total	$0	$0	$0

Income_Taxes_Summary_of_Unreco

Income Taxes - Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Beginning balance, Unrecognized tax benefits	$445,000	$437,000
Prior year tax position, Unrecognized tax benefits	0	0
Current year tax position, Unrecognized tax benefits	0	0
Deferred tax position, Unrecognized tax benefits	8,000	8,000
Settlements with tax authorities, Unrecognized tax benefits	0	0
Expiration of the statute of limitations, Unrecognized tax benefits	0	0
Ending balance, Unrecognized tax benefits	453,000	445,000
Beginning balance, Interest and penalties
Prior year tax position, Interest and penalties
Current year tax position, Interest and penalties
Deferred tax position, Interest and penalties
Settlements with tax authorities, Interest and penalties
Expiration of the statute of limitations, Interest and penalties
Ending balance at December, Interest and penalties

Employee_Benefit_Plan_Addition

Employee Benefit Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Defined contribution plan, maximum annual contribution per employee, percent	4.00%
Defined contribution plan, employer discretionary contribution amount	$79,737	$196,257	$201,510

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Dec. 31, 2011	Agreement	Dec. 31, 2013	Dec. 31, 2012
Commitment And Contingencies [Line Items]
Number of Agreements		5
Milestone payment & royalties		$0	$0
Unconditional purchase obligation		861,257
Upfront payment	82,983
Capital lease monthly payment		7,616
Capital lease term		36 months
Debt instrument, periodic payment		83,634	78,125	52,410
Debt instrument, periodic payment, interest		7,707	20,827	23,708
Impairment loss			105,491
Capital lease future minimum lease amount		4,500
Accumulated depreciation for leased equipment		27,622
Operating lease year of start		2015
Operating lease year of end		2019
Operating leases, rent expense		466,770	511,029	459,150
Scientific Equipment [Member]
Commitment And Contingencies [Line Items]
Capital lease obligations	$304,673

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Operating Leases (Detail) (USD $)	Dec. 31, 2014
Leases [Abstract]
2015	$377,623
2016	354,918
2017	365,565
2018	376,532
2019	191,048
Total minimum lease payments	$1,665,686

Quarterly_Financial_Data_Summa

Quarterly Financial Data - Summary of the Quarterly Consolidated Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenues	$1,390,432	$415,126	$562,087	$1,334,254	$3,871,632	$1,635,600	$1,613,262	$1,367,472	$3,701,899	$8,487,966	$3,570,710
Loss from Operations	-3,451,630	-3,438,739	-4,012,504	-3,519,062	-2,996,158	-5,856,468	-6,776,618	-7,447,515	-14,421,935	-23,076,759	-30,046,606
Net income (loss)	10,683,797	-4,615,663	-4,131,571	-1,901,197	-844,754	-4,610,961	-3,886,421	-10,787,148	35,366	-20,129,284	-22,414,640
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.	$11,271,771	($4,096,134)	($3,961,161)	($1,585,372)	($365,247)	($4,091,196)	($3,042,111)	($9,764,323)
Basic Earnings (Loss) Per Share Available for Common Shareholders	$3.95	($1.43)	($1.53)	($0.63)	($0.16)	($1.82)	($1.35)	($4.36)
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$3.95	($1.43)	($1.53)	($0.63)	($0.16)	($1.82)	($1.35)	($4.36)
Weighted Average Shares Outstanding, Basic	2,856,461	2,855,510	2,594,582	2,498,407	2,258,507	2,253,064	2,247,430	2,241,329
Weighted Average Shares Outstanding, Diluted	2,856,461	2,855,510	2,594,582	2,498,407	2,258,507	2,253,064	2,247,430	2,241,329

Subsequent_Events_Summary_of_O

Subsequent Events - Summary of Outstanding Warrants (Detail) (USD $)	0 Months Ended
	Feb. 06, 2015	Jun. 20, 2014	Jan. 16, 2014	Oct. 31, 2012
Schedule of Reverse Stock Split [Line Items]
Current exercise price		$10.10	$24.40	$40
Outstanding warrants				46,771
Subsequent Event [Member]
Schedule of Reverse Stock Split [Line Items]
Weighted average exercise price	$14.49
Current exercise price	$14.49
Outstanding warrants	2,281,332
Subsequent Event [Member] \| June Two Thousand And Eleven SeriesF Agent [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	17-Jun-15
Current exercise price	$100
Outstanding warrants	8,809
Subsequent Event [Member] \| Jan 2014 B [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	16-Jul-15
Current exercise price	$24.40
Outstanding warrants	45,291
Subsequent Event [Member] \| June Two Thousand And Eleven SeriesF [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	22-Jun-16
Current exercise price	$100
Outstanding warrants	73,414
Subsequent Event [Member] \| March Two Thousand And Ten [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	2-Mar-17
Current exercise price	$3
Outstanding warrants	46,771
Subsequent Event [Member] \| October Two Thousand And Twelve SeriesG [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	24-Oct-17
Current exercise price	$60
Outstanding warrants	215,638
Subsequent Event [Member] \| Two Thousand Nine Seriesd [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	30-Mar-18
Current exercise price	$3
Outstanding warrants	174,307
Subsequent Event [Member] \| Hercules [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	29-Sep-18
Current exercise price	$10.10
Outstanding warrants	7,813
Subsequent Event [Member] \| January Two Thousand And Fourteen SeriesA [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	16-Jan-19
Current exercise price	$24.40
Outstanding warrants	45,291
Subsequent Event [Member] \| June Two Thousand And Fourteen Seriesj [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	20-Jun-19
Current exercise price	$11.20
Outstanding warrants	155,510
Subsequent Event [Member] \| January Two Thousand And Fourteen Seriesa Modified [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	16-Jan-21
Current exercise price	$20.40
Outstanding warrants	102,460
Subsequent Event [Member] \| February Two Thousand Fifteen SeriesA [Member]
Schedule of Reverse Stock Split [Line Items]
Warrant expiration date	4-Aug-21
Current exercise price	$3.64
Outstanding warrants	1,406,028

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended
Subsequent Events - Additional Information (Detail) (USD $)	Feb. 06, 2015	Jan. 31, 2015	Dec. 31, 2014	Jun. 20, 2014	Jan. 16, 2014	Dec. 31, 2013	Oct. 31, 2012	Feb. 06, 2014	Dec. 31, 2012
Schedule of Reverse Stock Split [Line Items]
Sales of common stock , shares			2,858,126			2,259,818
Common stock, price per share			$5.60	$11.35	$24.40	$23.40	$40
Series A Convertible preferred stock, price per share			$0.01			$0.01
Exercise Price of warrants				$10.10	$24.40		$40
Preferred stock, stated value
Preferred stock, shares outstanding			0			0
Common shares, shares outstanding			2,858,126			2,259,818
Number of common stock issuable under pre-funded warrants			160,000,000			160,000,000
Issue price			$0.01			$0.01
Shares outstanding under options			261,389			278,390
Outstanding warrants							46,771
Employee Stock Option [Member]
Schedule of Reverse Stock Split [Line Items]
Shares outstanding under options			261,389					261,470
Weighted average exercisable price								$67.89
Warrants [Member]
Schedule of Reverse Stock Split [Line Items]
Exercise Price of warrants			$33.72			$54			$58.80
Outstanding warrants			875,304			526,752			518,939
Subsequent Event [Member]
Schedule of Reverse Stock Split [Line Items]
Sales of common stock , shares	572,205
Investment in Series A convertible preferred stock, shares	239,135
Total investment	4,200,000
Shares issuable	1,406,028
Exercise Price of warrants	$14.49
Common shares, shares outstanding	3,435,354
Outstanding warrants	2,281,332
Subsequent Event [Member] \| Board Of Directors [Member]
Schedule of Reverse Stock Split [Line Items]
Shares issued in lieu of cash compensation		5,023
Subsequent Event [Member] \| Series A Warrants [Member]
Schedule of Reverse Stock Split [Line Items]
Warrants issued	1,406,028
Exercise Price of warrants	$3.64
Subsequent Event [Member] \| Series B Pre-funded Warrants [Member]
Schedule of Reverse Stock Split [Line Items]
Sales of common stock , shares	594,688
Common stock, price per share	$3
Common shares, shares outstanding	4,269,177
Number of common stock issuable under pre-funded warrants	594,688
Issue price	$3
Subsequent Event [Member] \| Preferred Class A [Member]
Schedule of Reverse Stock Split [Line Items]
Investment in series A convertible preferred stock	717,400
Series A Convertible preferred stock, price per share	$3
Investment in Series A convertible preferred stock, shares	239,135
Preferred stock, stated value	$1,000
Preferred stock, shares outstanding	717.4
Issue price	$3
Subsequent Event [Member] \| Warrants [Member] \| Rusnano and Panacela [Member]
Schedule of Reverse Stock Split [Line Items]
Exercise Price of warrants	$33.88
Outstanding warrants	38,504